ORIGINAL

FORM PTO-1390 (REV. 11-2000) U S DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371

ATTORNEY 'S DOCKET NUMBER: **Le A 33 469**

U S APPLICATION NO (If known, see 37 CFR 1 5): 09/930243

INTERNATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED
PCT/EP00/04417	**16 May 2000 (16.05.00)**	**29 May 1999 (29.05.99)**

TITLE OF INVENTION: **SUBSTITUTED PHENYLCYCLOHEXANE CARBOXYLIC ACID AMIDES THAT HAVE AN ADENOSINE UPTAKE INHIBITING EFFECT**

APPLICANT(S) FOR DO/EO/US: **FREUND, et al.**

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. [X] This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. [ ] This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. [X] This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.
4. [X] The US has been elected by the expiration of 19 months from the priority date (Article 31).
5. [X] A copy of the International Application as filed (35 U.S.C. 371(c)(2))
   a. [X] is attached hereto (required only if not communicated by the International Bureau).
   b. [ ] has been communicated by the International Bureau.
   c. [ ] is not required, as the application was filed in the United States Receiving Office (RO/US).
6. [X] An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
   a. [X] is attached hereto.
   b. [ ] has been previously submitted under 35 U.S.C. 154(d)(4).
7. [X] Amendments to the claims of the International Aplication under PCT Article 19 (35 U.S.C. 371(c)(3))
   a. [ ] are attached hereto (required only if not communicated by the International Bureau).
   b. [ ] have been communicated by the International Bureau.
   c. [ ] have not been made; however, the time limit for making such amendments has NOT expired.
   d. [X] have not been made and will not be made.
8. [ ] An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).
9. [X] An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. [ ] An English lanugage translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11 to 20 below concern document(s) or information included:

11. [X] An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. [ ] An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. [X] A FIRST preliminary amendment.
14. [ ] A SECOND or SUBSEQUENT preliminary amendment.
15. [ ] A substitute specification.
16. [ ] A change of power of attorney and/or address letter.
17. [ ] A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.
18. [ ] A second copy of the published international application under 35 U.S.C. 154(d)(4).
19. [ ] A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
20. [X] Other items or information:
    1) **Certificate of Mailing under 37 C.F.R. 1.10;**
    2) **Transmittal of Information Disclosure Statement under 37 C.F.R. 1.97(b);**
    3) **Information Disclosure Citation (Modified Form PTO-1449) and references cited therein**
    4) **Return Receipt Postcard.**

Date of Deposit: 29 November 2001
Express Mail Label No.: ET386113124US

29 NOV 2001

U.S. APPLICATION NO (if known, see 37 CFR 1.5)	INTERNATIONAL APPLICATION NO	ATTORNEY'S DOCKET NUMBER
09/980243	PCT/EP00/04417	Le A 33 469

21. [X] The following fees are submitted:

	CALCULATIONS PTO USE ONLY	
BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)):		
Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO **$1000.00**		
International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO ..... ~~**$860.00**~~ **$890.00**		
International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO **$710.00**		
International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) **$690.00**		
International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) **$100.00**		
ENTER APPROPRIATE BASIC FEE AMOUNT =	$ **890.00**	
Surcharge of **$130.00** for furnishing the oath or declaration later than [ ] 20 [ ] 30 months from the earliest claimed priority date (37 CFR 1.492(e)).	$	

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	**21** - 20 =	**1**	x **$18.00**	$ **18.00**	
Independent claims	**12** - 3 =	**9**	x ~~**$80.00**~~ **84.00**	$ **756.00**	
MULTIPLE DEPENDENT CLAIM(S) (if applicable)	**1**		+ ~~**$270.00**~~**280.00**	$ **280.00**	
TOTAL OF ABOVE CALCULATIONS =				$ **1,944.00**	
[ ] Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2. +				$	
SUBTOTAL =				$ **1,944.00**	
Processing fee of **$130.00** for furnishing the English translation later than [ ] 20 [ ] 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				$	
TOTAL NATIONAL FEE =				$ **1,944.00**	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). **$40.00** per property +				$	
TOTAL FEES ENCLOSED =				$ **1,944.00**	
				Amount to be refunded:	$
				charged:	$

a. [ ] A check in the amount of $ _____ to cover the above fees is enclosed.

b. [X] Please charge my Deposit Account No. **13-3372** in the amount of $ **1,944.00** to cover the above fees. A duplicate copy of this sheet is enclosed.

c. [X] The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. **13-3372** . A duplicate copy of this sheet is enclosed.

d. [ ] Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. **Credit card information should not be included on this form.** Provide credit card information and authorization on PTO-2038.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137 (a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Jeffrey M. Greenman
Vice President, Patents and Licensing
Bayer Corporation
400 Morgan Lane
West Haven, CT 06516

William F. Gray
SIGNATURE

William F. Gray
NAME

31,018
REGISTRATION NUMBER

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Freund, e al. Group Art Unit:

Serial No: National Stage Filing of PCT/EP00/04417

Examiner:

Filed: herewith

For: Substituted Phenylcyclohexane Carboxylic Acid Amides that have an Adenosine Uptake Inhibiting Effect

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

This preliminary amendment is submitted in the above-identified national stage application of PCT/EP00/04417 filed on even date herewith.

Please amend the above-identified application as follows:

In the claims:

Please cancel claims12-14.

Please amend claims 1-2 and 5-11 as shown below:

Please add new claims 15-21 as shown below:

1. (Amended) Compounds of the general formula (I)



(I),

in which

A, D, E and G are identical or different and represent CH groups or nitrogen atoms,

L^1 and L^2 are identical or different and independently of one another each represents one or more radicals selected from the group consisting of hydrogen, halogen, hydroxyl, carboxyl, cyano, nitro, trifluoromethyl, trifluormethoxy, $(C_1$-$C_6)$-alkyl, $(C_1$-$C_6)$-alkoxy and $(C_1$-$C_6)$-alkoxy-carbonyl,

R^1 represents the CH_2-OH group, or
represents a radical of the formula CO-NR^4R^5

in which

R^4 and R^5 are identical or different and each represents hydrogen or $(C_1$-$C_6)$-alkyl,

R^2 represents $(C_3$-$C_8)$-cycloalkyl,
represents $(C_1$-$C_8)$-alkyl which is optionally interrupted by an oxygen or sulphur atom or by a radical NR^6,
represents a 4- to 8-membered saturated heterocycle which is attached to the imidazole ring via a nitrogen atom and which optionally contains a further oxygen or sulphur atom, or

represents a 4- to 8-membered saturated hetrocycle which contains a radical of the formula NR^7 and optionally additionally one nitrogen, oxygen or sulphur atom,

where (C_3-C_8)-cycloalkyl, (C_1-C_8)-alkyl which is optionally interrupted by one oxygen or sulphur atom, the 4- to 8-membered saturated heterocycle which is attached to the imidazole ring via a nitrogen atom and which optionally contains one further oxygen or sulphur atom and optionally (C_1-C_8)-alkyl which is interrupted by a radical of the formula NR^6 and optionally the 4- to 8-membered saturated heterocycle which contains a radical of the formula NR^7 and optionally additionally one nitrogen or sulphur atom are substituted by one to three hydroxyl groups and/or by a radical of the formula $-NR^8R^9$

in which

R^6 and R^7 are identical or different and each represents hydrogen, (C_1-C_6)-alkyl, hydroxy-(C_1-C_6)-alkyl or (C_3-C_7)-cycloalkyl,

R^8 and R^9 are identical or different and each represents hydrogen, (C_1-C_6)-alkyl or (C_3-C_7)-cycloalkyl,

or

R^8 and R^9 together with the nitrogen atom form a 4- to 8-membered saturated heterocycle which may optionally additionally contain one oxygen or sulphur atom or a radical of the formula NR^{10}

in which

R^{10} represents hydrogen, $(C_1\text{-}C_6)$-alkyl or $(C_3\text{-}C_7)$-cycloalkyl

and

R^3 represents a phenyl, naphthyl, pyrimidinyl, pyridyl, furyl or thienyl ring, where the rings are optionally mono- or polysubstituted by radicals selected from the group consisting of halogen, hydroxyl, carboxyl, cyano, nitro, trifluoromethyl, trifluoromethoxy, $(C_1\text{-}C_6)$-alkyl, $(C_1\text{-}C_6)$-alkoxy and $(C_1\text{-}C_6)$-alkoxycarbonyl,

and their salts.

2. (Amended) Compounds according to Claim 1

where

A, D, E and G each represent the CH group,

or one of the radicals A, D, E and G represents a nitrogen atom and the others each represent the CH group,

L^1 and L^2 are identical or different and independently of one another each represents one or more radicals selected from the group consisting of hydrogen, fluorine, chlorine, cyano, trifluoromethyl [or] and trifluoromethoxy,

R^1 represents the $-CH_2$-OH group, or
represents a radical of the formula $-CO\text{-}NR^4R^5$

in which

R^4 and R^5 are identical or different and each represents hydrogen or $(C_1\text{-}C_3)$-alkyl,

R^2 represents (C_3-C_7)-cycloalkyl,

represents (C_1-C_6)-alkyl which is optionally interrupted by an oxygen or sulphur atom or by a radical NR^6,

represents a 5- to 7-membered saturated heterocycle which is attached to the imidazole ring via a nitrogen atom and which optionally contains a further oxygen or sulphur atom, or

represents a 5- to 7-membered saturated heterocycle which contains a radical of the formula NR^7 and optionally additionally one nitrogen, oxygen or sulphur atom,

where (C_3-C_7)-cycloalkyl, (C_1-C_6)-alkyl which is optionally interrupted by one oxygen or sulphur atom, the 5- to 7-memebered saturated heterocycle which is attached to the imidazole ring via a nitrogen atom and which optionally contains one further oxygen or sulphur atom and optionally (C_1-C_6)-alkyl which is interrupted by a radical of the formula NR^6 and optionally the 5- to 7-membered saturated heterocycle which contains a radical of the formula NR^7 and optionally additionally one nitrogen, oxygen or sulphur atom are substituted by one to three hydroxyl groups and/or by a radical of the formula $-NR^8R^9$

in which

R^6 and R^7 are identical or different and each represents hydrogen, (C_1-C_4)-alkyl, hydroxy-(C_1-C_4)-alkyl or (C_3-C_6)-cycloalkyl,

R^8 and R^9 are identical or different and each represents hydrogen, (C_1-C_4)-alkyl or (C_3-C_6)-cycloalkyl,

or

R^8 and R^9 together with the nitrogen atom form a 5- to 7-membered saturated heterocycle which may optionally additionally contain one oxygen or sulphur atom or a radical of the formula NR^{10}

in which

R^{10} represents hydrogen, $(C_1$-$C_4)$-alkyl or $(C_3$-$C_6)$-cycloalkyl

and

R^3 represents a phenyl, pyridyl or thienyl ring, which is optionally mono- or polysubstituted by radicals selected from the group consisting of fluorine, chlorine, cyano, trifluoromethyl and trifluoromethoxy,

and their salts.

5. (Amended) Process for preparing compounds of the general formula (I) according to Claim 1, characterized in that

(A) compounds of the general formula (II)



(II),

in which

L^2 is as defined in Claim 1,

T represents (C_1-C_4)-alkyl,

and

V represents a suitable leaving group,

is initially coverted by reaction with compounds of the general formula (III)



(III),

in which

A, D, E, G and L^1 are each as defined in Claim 1

and

R^{11} has the meaning of R^2 given in Claim 1, where amino and hydroxyl functions are optionally blocked by suitable amino or hydroxyl protective groups,

in inert solvents, depending on the definition of R^{11} optionally in the presence of a base, into the compounds of the general formula (IV)



(IV),

in which

R^{11}, A, D, E,G, L^1, L^2 and T are each as defined above,

which are converted in a subsequent step using acids or bases into the corresponding carboxylic acids of the general formula (V)



(V),

in which

R^{11}, A, D, E, G, L^1 and L^2 are each as defined above,

which are subsequently reacted with compounds of the general formula (VI)



(VI),

in which

R^1 and R^3 are each as defined in Claim 1

in inert solvents,

and, if R^{11} carries one of the abovementioned protective groups, these are optionally removed by customary methods either in the hydrolysis to the acids (IV)- >(V) or after the reaction with the compounds of the general formula (VI),

or

(B) if R^2 of structure (I) shown in Claim 1 represents a saturated heterocycle which is attached directly via a nitrogen atom to the imidazole ring,

the abovementioned compounds of the general formula (II) are initially converted with compounds of the general formula (IIIa)



(IIIa) ,

in which

A, D, E, G and L^1 are each as defined in Claim 1

and

Y represents halogen or mesyl,

in inert solvents into the corresponding compounds of the formula (VII)



(VII) ,

in which

Y, A, D, E, G, L^1, L^2 and T are each as defined above,

which are reacted in a subsequent step with compounds of the general formula (VIII)

$$HNR^{12}R^{13} \qquad \text{(VIII)}$$

in which

R^{12} and R^{13} together with the nitrogen atom form a heterocycle according to the definition of R^2

to give compounds of the general formula (IX)



(IX),

in which

A, D, E, G, L^1, L^2, R^{12}, R^{13} and T are each as defined above,

which are, in the subsequent steps, converted as described under (A) by hydrolysis into the corresponding carboxylic acids of the general formula (X)



(X),

in which

A, D, E, G, L^1, L^2, R^{12}, and R^{13} are each defined above,

and these compounds are subsequently reacted with the compounds of the general formula (VI) according to known methods for preparing amides from carboxylic acids and amines and, if appropriate, converted into the corresponding salts by reaction with an acid.

6. (Amended) Compounds of the general formula (IV)



(IV),

in which

A, D, E, G, L^1, and L^2, are each as defined in Claim 1 and R^{11} and T are defined as in Claim 5

and their salts.

7. (Amended) Compounds of the general formula (V)



(V),

in which

A, D, E, G, L^1, and L^2, are each as defined in Claim 1 and R^{11} is as defined in Claim 5

and their salts.

8. (Amended) Compounds of the general formula (VII)



(VII) ,

in which

A, D, E, G, L^1, and L^2, are each as defined in Claim 1 and Y and T are as defined in Claim 5

and their salts.

9. (Amended) Compounds of the general formula (IX)



(IX)

in which

A, D, E, G, L^1, and L^2, are each as defined in Claim 1 and R^{12}, R^{13} and T are as defined in Claim 5.

and their salts.

10. (Amended) Compounds of the general formula (X)



(X)

in which

A, D, E, G, L^1, and L^2, are each as defined in Claim 1 and R^{12} and R^{13} are as defined in claim 5

and their salts.

11. (Amended) A pharmaceutical composition comprising a compound of the general formula (I) according to Claim 1 in admixture with at least one pharmaceutically acceptable, essentially non-toxic carrier or excipient.

15. The process of claim 5 wherein T represents methyl or tert-butyl.

16. The process of claim 5 wherein V represents halogen, mesylate or tosylate.

17. The process of claim 16 wherein V represents bromine.

18. The process of claim 5 wherein the group Y of structure IIIa represents chorine or bromine.

19. A method of treatment or prophylaxis of an ischaemic brain disorder in a mammal, comprising administering an effective amount of a compound of claim 1.

20. The method of claim 19 wherein said mammal is human.

21. The method of claim 19 wherein said ischaemic brain disorder is stroke, reperfusion damage, or brain trauma.

Remarks / Explanations

As a result of this preliminary amendment, claims 1-11 and 15-21 are pending in the application. Claims 12-14 have been canceled. Claims 1, 2 and 5-11 have been amended. New claims 15-21 have been added.

New claims 15-18 recite matter deleted from original claim 5. New claims 19-21 replace original claims 12-14.

No new matter has been added.

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page is captioned **"Version with markings to show changes made."**

In view of the above amendments and explanations, this application is deemed to be in condition for allowance, and allowance is accordingly requested.

Respectfully submitted,

William F. Gray
Bayer Corporation
400 Morgan Lane
West Haven, CT 06516-4175

Reg. No. 31018
Phone: (203) 812-2712
Date: 11/29/01

Version with markings to show changes made:

1. (Amended) Compounds of the general formula (I)



(I),

in which

A, D, E and G are identical or different and represent CH groups or nitrogen atoms,

[L1] L^1 and [L2] L^2 are identical or different and independently of one another each represents one or more radicals selected from the group consisting of hydrogen, halogen, hydroxyl, carboxyl, cyano, nitro, trifluoromethyl, trifluormethoxy, [(C1-C6)] (C_1-C_6)-alkyl, [(C1-C6)] (C_1-C_6)-alkoxy [or (C1-C6)] and (C_1-C_6)-alkoxy-carbonyl,

R^1 represents the CH_2-OH group, or
represents a radical of the formula CO-NR^4R^5

in which

R^4 and R^5 are identical or different and each represents hydrogen or (C_1-C_6)-alkyl,

R^2 represents (C_3-C_8)-cycloalkyl,

represents (C_1-C_8)-alkyl which is optionally interrupted by an oxygen or sulphur atom or by a [radial] radical NR^6,

represents a 4- to 8-membered saturated heterocycle which is attached to the imidazole ring via a nitrogen atom and which optionally contains a further oxygen or sulphur atom, or

represents a 4- to 8-membered saturated hetrocycle which contains a radical of the formula NR^7 and optionally additionally one nitrogen, oxygen or sulphur atom,

where (C_3-C_8)-cycloalkyl, (C_1-C_8)-alkyl which is optionally interrupted by one oxygen or sulphur atom, the 4- to 8-membered saturated heterocycle which is attached to the imidazole ring via a nitrogen atom and which optionally contains one further oxygen or sulphur atom and optionally (C_1-C_8)-alkyl which is interrupted by a radical of the formula NR^6 and optionally the 4- to 8-membered saturated heterocycle which contains a radical of the formula NR^7 and optionally additionally one nitrogen or sulphur atom are substituted by one to three hydroxyl groups and/or by a radical of the formula $-NR^8R^9$

in which

R^6 and R^7 are identical or different and each represents hydrogen, (C_1-C_6)-alkyl, hydroxy-(C_1-C_6)-alkyl or (C_3-C_7)-cycloalkyl,

R^8 and R^9 are identical or different and each represents hydrogen, (C_1-C_6)-alkyl or (C_3-C_7)-cycloalkyl,

or

R^8 and R^9 together with the nitrogen atom form a 4- to 8-membered saturated heterocycle which may optionally additionally contain one oxygen or sulphur atom or a radical of the formula NR^{10}

in which

R^{10} represents hydrogen, (C_1-C_6)-alkyl or (C_3-C_7)-cycloalkyl

and

R^3 represents a phenyl, naphthyl, pyrimidinyl, pyridyl, furyl or thienyl ring, where the rings are optionally mono- or polysubstituted by radicals selected from the group consisting of halogen, hydroxyl, carboxyl, cyano, nitro, trifluoromethyl, trifluoromethoxy, (C_1-C_6)-alkyl, (C_1-C_6)-alkoxy[or]<u>and</u> (C_1-C_6)-alkoxycarbonyl,

and their salts.

2. (Amended) Compounds according to Claim 1

where

A, D, E and G each represent the CH group,

or one of the radicals A, D, E and G represents a nitrogen atom and the others each represent the CH group,

L^1 and L^2 are identical or different and independently of one another each represents one or more radicals selected from the group consisting of hydrogen, fluorine, chlorine, cyano, trifluoromethyl [or] <u>and</u> trifluoromethoxy,

R^1 represents the $-CH_2$-OH group, or

represents a radical of the formula $-CO-NR^4R^5$

in which

R^4 and R^5 are identical or different and each represents hydrogen or (C_1-C_3)-alkyl,

R^2 represents (C_3-C_7)-cycloalkyl,

represents (C_1-C_6)-alkyl which is optionally interrupted by an oxygen or sulphur atom or by a radical NR^6,

represents a 5- to 7-membered saturated heterocycle which is attached to the imidazole ring via a nitrogen atom and which optionally contains a further oxygen or sulphur atom, or

represents a 5- to 7-membered saturated heterocycle which contains a radical of the formula NR^7 and optionally additionally one nitrogen, oxygen or sulphur atom,

where (C_3-C_7)-cycloalkyl, (C_1-C_6)-alkyl which is optionally interrupted by one oxygen or sulphur atom, the 5- to 7-memebered saturated heterocycle which is attached to the imidazole ring via a nitrogen atom and which optionally contains one further oxygen or sulphur atom and optionally (C_1-C_6)-alkyl which is interrupted by a radical of the formula NR^6 and optionally the 5- to 7-membered saturated heterocycle which contains a radical of the formula NR^7 and optionally additionally one nitrogen, oxygen or sulphur atom are substituted by one to three hydroxyl groups and/or by a radical of the formula $-NR^8R^9$

in which

R^6 and R^7 are identical or different and each represents hydrogen, (C_1-C_4)-alkyl, hydroxy-(C_1-C_4)-alkyl or (C_3-C_6)-cycloalkyl,

R^8 and R^9 are identical or different and each represents hydrogen, (C_1-C_4)-alkyl or (C_3-C_6)-cycloalkyl,

or

R^8 and R^9 together with the nitrogen atom form a 5- to 7-membered saturated heterocycle which may optionally additionally contain one oxygen or sulphur atom or a radical of the formula NR^{10}

in which

R^{10} represents hydrogen, (C_1-C_4)-alkyl or (C_3-C_6)-cycloalkyl

and

R^3 represents a phenyl, pyridyl or thienyl ring, which is optionally mono- or polysubstituted by radicals selected from the group consisting of fluorine, chlorine, cyano, trifluoromethyl [or] <u>and</u> trifluoromethoxy,

and their salts.

5. (Amended) Process for preparing compounds of the general formula (I) according to Claim[s] 1 [to 4], characterized in that

[[A]] <u>(A)</u> compounds of the general formula (II)



(II),

in which

L^2 is as defined in Claim 1,

T represents (C_1-C_4)-alkyl, [preferably methyl or tert-butyl,]

and

V represents a suitable leaving group, [such as, for example, halogen, mesylate or tosylate, preferably bromine,]

is initially coverted by reaction with compounds of the general formula (III)



(III),

in which

A, D, E, G and L^1 are each as defined in Claim 1

and

R^{11} has the meaning of R^2 given in Claim 1, where amino and hydroxyl functions are optionally blocked by suitable amino or hydroxyl protective groups,

in inert solvents, depending on the definition of R^{11} optionally in the presence of a base, into the compounds of the general formula (IV)



(IV),

in which

R^{11}, A, D, E,G, L^1, L^2 and [t] T are each as defined above,

which are converted in a subsequent step using acids or bases into the corresponding carboxylic acids of the general formula (V)



(V),

in which

R^{11}, A, D, E, G, L^1 and L^2 are each as defined above,

which are subsequently reacted [by known methods] with compounds of the general formula (VI)



(VI),

in which

R^1 and R^3 are each as defined in Claim 1

in inert solvents,

and, if R^{11} carries one of the abovementioned protective groups, these are optionally removed by customary methods either in the hydrolysis to the acids (IV)- >(V) or after the reaction with the compounds of the general formula (VI),

or

[[B]] (B) if R^2 of structure (I) shown in Claim 1 represents a saturated heterocycle which is attached directly via a nitrogen atom to the imidazole ring,

the abovementioned compounds of the general formula (II) are initially converted with compounds of the general formula (IIIa)



(IIIa) ,

in which

A, D, E, G and L^1 are each as defined in Claim 1

and

Y represents halogen or mesyl, [preferably chlorine, bromine, or mesyl,]

in inert solvents into the corresponding compounds of the formula (VII)



(VII),

in which

Y, A, D, E, G, L^1, L^2 and T are each as defined above,

which are reacted in a subsequent step with compounds of the general formula (VIII)

$$HNR^{12}R^{13} \qquad \text{(VIII)}$$

in which

R^{12} and R^{13} together with the nitrogen atom form a heterocycle according to the definition of R^2

to give compounds of the general formula (IX)



(IX),

in which

A, D, E, G, L^1, L^2, R^{12}, R^{13} and T are each as defined above,

which are, in the subsequent steps, converted as described under [[A]] (A) by hydrolysis into the corresponding carboxylic acids of the general formula (X)



(X),

in which

A, D, E, G, L^1, L^2, R^{12}, and R^{13} are each defined above,

and these compounds are subsequently reacted with the compounds of the general formula (VI) according to known methods for preparing amides from carboxylic acids and amines and, if appropriate, converted into the corresponding salts by reaction with an acid.

6. (Amended) Compounds of the general formula (IV)



(IV),

in which

A, D, E, G, L^1, and L^2, [R^{11} and T] are each as defined in Claim[s]1 [and 5] and R^{11} and T are defined as in Claim 5

and their salts.

7. (Amended) Compounds of the general formula (V)



(V),

in which

A, D, E, G, L^1, and L^2, [and R^{11}] are each as defined in Claim[s] 1 [and 5] and R^{11} is as defined in Claim 5

and their salts.

8. (Amended) Compounds of the general formula (VII)



(VII),

in which

A, D, E, G, L^1, and L^2, [Y and T] are each as defined in Claim[s] 1 [and 5] and Y and T are as defined in Claim 5

and their salts.

9. (Amended) Compounds of the general formula (IX)



(IX)

in which

A, D, E, G, L^1, and L^2, [R^{12}, R^{13} and T] are each as defined in Claim[s]1 [and 5] and R^{12}, R^{13} and T are as defined in Claim 5.

and their salts.

10. (Amended) Compounds of the general formula (X)



(X)

in which

A, D, E, G, L^1, and L^2, [$R^{11}$and R^{12}] are each as defined in Claim[s]1 [and 5] and R^{12} and R^{13} are as defined in claim 5

and their salts.

11. (Amended) [Medicaments,] <u>A pharmaceutical composition</u> comprising a compound of the general formula (I) according to [any of] Claim[s] 1 [to 4] in admixture with at least one pharmaceutically acceptable, essentially non-toxic carrier or excipient.

Substituted phenylcyclohexanecarboxamides

The present invention relates to substituted phenylcyclohexanecarboxamides having adenosine-uptake-inhibiting action, to processes for their preparation and to their use in medicaments, in particular for treating ischaemic brain disorders.

Adenosine is an endogenic effector with cell-protective activity, in particular under cell-damaging conditions with limited oxygen and substrate supply, such as, for example, in ischaemia, stroke and brain trauma. The neuroprotective action of adenosine is essentially effected via suppression of presynaptic glutamate release and limitation of postsynaptic depolarization. This prevents toxic calcium influx into postsynaptic nerve cells via NMDA receptors. Under ischaemic or hypoxic conditions, the extracellular concentration of adenosine in the CNS is dramatically increased.

There are various indications of a neuroprotective, anticonvulsive, analgesic and sleep-inducing potential of adenosine-uptake inhibitors, since they enhance the intrinsic effects of adenosine by inhibiting its cellular reuptake. Accordingly, adenosine-uptake inhibitors can be administered orally or intravenously for the prevention and treatment of cerebral ischaemia, stroke, reperfusion damage, brain trauma, oedema, spasms, epilepsy, respiratory arrest, cardiac arrest, Reye's syndrome, cerebral thrombosis, emboli, tumours, haemorrhages, encephalomyelitis, hydroencephalitis, spinal injuries, post-operative brain damage, injuries to the retina or the optical nerve after glaucoma, ischaemia, hypoxia, oedema or trauma and in the treatment of schizophrenia, sleep disturbances and pain (*Cerebrovasc. Brain Metab. Rev.* **1992**, *4*, 364-369; *Drug Dev. Res.* **1993**, *28*, 410-415; *Science* **1997**, *276*, 1265-1268; *'Adenosine in the Nervous System'*, Ed.: Trevor Stone, Academic Press Ltd. 1991, 217-227; *Ann. Rep. Med. Chem.* **1998**, *33*, 111-120).

Adenosine-uptake inhibitors can also be employed for potentiating the effect of nucleobase, nucleoside or nucleotide antimetabolites in the chemotherapeutical treatment of cancer and antiviral (for example HIV) chemotherapy (*Curr. Med. Chem.* 1997, *4*, 35-66).

EP-A-0 611 767 and EP-A-0 725 064 disclose phenylcyclohexylcarboxamides which can be used for treating atherosclerosis and/or restenosis.

The present invention relates to compounds of the general formula (I)



(I),

in which

A, D, E and G are identical or different and represent CH groups or nitrogen atoms,

L^1 and L^2 are identical or different and independently of one another each represents one or more radicals selected from the group consisting of hydrogen, halogen, hydroxyl, carboxyl, cyano, nitro, trifluoromethyl, trifluoromethoxy, (C_1-C_6)-alkyl, (C_1-C_6)-alkoxy or (C_1-C_6)-alkoxy-carbonyl,

R^1 represents the CH_2-OH group, or
represents a radical of the formula $CO-NR^4R^5$

in which

R^4 and R^5 are identical or different and each represents hydrogen or (C_1-C_6)-alkyl,

R^2 represents (C_3-C_8)-cycloalkyl,
represents (C_1-C_8)-alkyl which is optionally interrupted by an oxygen or sulphur atom or by a radial NR^6,
represents a 4- to 8-membered saturated heterocycle which is attached to the imidazole ring via a nitrogen atom and which optionally contains a further oxygen or sulphur atom, or

represents a 4- to 8-membered saturated heterocycle which contains a radical of the formula NR^7 and optionally additionally one nitrogen, oxygen or sulphur atom,

where (C_3-C_8)-cycloalkyl, (C_1-C_8)-alkyl which is optionally interrupted by one oxygen or sulphur atom, the 4- to 8-membered saturated heterocycle which is attached to the imidazole ring via a nitrogen atom and which optionally contains one further oxygen or sulphur atom and optionally (C_1-C_8)-alkyl which is interrupted by a radical NR^6 and optionally the 4- to 8-membered saturated heterocycle which contains a radical of the formula NR^7 and optionally additionally one nitrogen, oxygen or sulphur atom are substituted by one to three hydroxyl groups and/or by a radical of the formula $-NR^8R^9$

in which

R^6 and R^7 are identical or different and each represents hydrogen, (C_1-C_6)-alkyl, hydroxy-(C_1-C_6)-alkyl or (C_3-C_7)-cycloalkyl,

R^8 and R^9 are identical or different and each represents hydrogen, (C_1-C_6)-alkyl or (C_3-C_7)-cycloalkyl,

or

R^8 and R^9 together with the nitrogen atom form a 4- to 8-membered saturated heterocycle which may optionally additionally contain one oxygen or sulphur atom or a radical of the formula NR^{10}

in which

R^{10} represents hydrogen, (C_1-C_6)-alkyl or (C_3-C_7)-cycloalkyl

and

R^3 represents a phenyl, naphthyl, pyrimidinyl, pyridyl, furyl or thienyl ring, where the rings are optionally mono- or polysubstituted by radicals selected from the group consisting of halogen, hydroxyl, carboxyl, cyano,

nitro, trifluoromethyl, trifluoromethoxy, (C_1-C_6)-alkyl, (C_1-C_6)-alkoxy or (C_1-C_6)-alkoxycarbonyl,

and their salts.

Physiologically acceptable salts of the compounds according to the invention can be salts of the substances according to the invention with mineral acids, carboxylic acids or sulphonic acids. Particular preference is given, for example, to salts with hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methanesulphonic acid, ethanesulphonic acid, toluenesulphonic acid, benzenesulphonic acid, naphthalenedisulphonic acid, acetic acid, propionic acid, lactic acid, tartaric acid, citric acid, fumaric acid, maleic acid or benzoic acid.

The compounds of the general formula (I) according to the invention can occur in different stereoisomeric forms which are either like image and mirror image (enantiomers), or which are not like image and mirror image (diastereomers). The invention relates both to the enantiomers and to the diastereomers and their respective mixtures. The racemic forms, like the diastereomers, can be separated in a known manner into the stereoisomerically uniform components.

Furthermore, certain compounds can be present in tautomeric forms. This is known to the person skilled in the art, and such compounds are likewise included in the scope of the invention.

(C_1-C_8)-Alkyl, (C_1-C_6)-alkyl etc., represent a straight-chain or branched alkyl radical having 1 to 8 or 1 to 6 carbon atoms. Examples which may be mentioned are: methyl, ethyl, n-propyl, isopropyl, tert-butyl, n-pentyl and n-hexyl. Preference is given to a straight-chain or branched alkyl radical having 1 to 4 carbon atoms (C_1-C_4). Particular preference is given to a straight-chain or branched alkyl radical having 1 to 3 carbon atoms (C_1-C_3).

(C_1-C_8)-Alkyl, (C_1-C_6)-alkyl etc., which is interrupted by one oxygen or sulphur atom and which is substituted by one to three hydroxyl groups and/or by a radical of the formula $-NR^8R^9$ represents, for example, 1,3-dihydroxy-prop-2-oxy-methyl, 2-hydroxy-ethoxy-methyl, 2-hydroxy-prop-1-oxy-methyl, 3-hydroxy-prop-1-oxy-methyl, morpholin-4-yl-methyl, piperidin-1-yl-methyl, 2-amino-ethyl, 2-dimethylamino-ethyl or diethylamino-methyl.

$(C_1$-$C_8)$-Alkyl, $(C_1$-$C_6)$-alkyl etc., which is interrupted by a radical N^6 and which is optionally substituted by one to three hydroxyl groups and/or by a radical of the formula $-NR^8R^9$ represents, for example, N-(2-hydroxy-ethyl)-aminomethyl, N-(2-hydroxy-ethyl)-N-methyl-aminomethyl or N,N-bis-(2-hydroxy-ethyl)-aminomethyl.

Hydroxy-$(C_1$-$C_6)$-alkyl or hydroxy-$(C_1$-$C_4)$-alkyl represents a straight-chain or branched alkyl radical having 1 to 6 or 1 to 4 carbon atoms. The examples which may be mentioned are: hydroxymethyl, 2-hydroxy-ethyl, 2-hydroxy-prop-1-yl, 3-hydroxy-prop-1-yl, 3-hydroxy-prop-2-yl, 2-hydroxy-but-1-yl, 5-hydroxy-pent-1-yl and 6-hydroxy-hex-1-yl. Preference is given to 2-hydroxy-ethyl.

$(C_1$-$C_6)$-Alkoxy represents a straight-chain or branched alkoxy radical having 1 to 6 carbon atoms. Examples which may be mentioned are: methoxy, ethoxy, n-propoxy, isopropoxy, tert-butoxy, n-pentoxy and n-hexoxy. Preference is given to a straight-chain or branched alkoxy radical having 1 to 4 carbon atoms $(C_1$-$C_4)$. Particular preference is given to a straight-chain or branched alkoxy radical having 1 to 3 carbon atoms $(C_1$-$C_3)$.

$(C_1$-$C_6)$-Alkoxycarbonyl represents a straight-chain or branched alkoxycarbonyl radical having 1 to 6 carbon atoms. Examples which may be mentioned are: methoxycarbonyl, ethoxycarbonyl, n-propoxycarbonyl, isopropoxycarbonyl and tert-butoxycarbonyl. Preference is given to a straight-chain or branched alkoxycarbonyl radical having 1 to 4 carbon atoms $(C_1$-$C_4)$. Particular preference is given to a straight-chain or branched alkoxycarbonyl radical having 1 to 3 carbon atoms $(C_1$-$C_3)$.

$(C_3$-$C_8)$-Cycloalkyl, $(C_3$-$C_7)$-cycloalkyl etc., represents, in the context of the invention, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl. Cyclopropyl, cyclopentyl and cyclohexyl may be mentioned as being preferred.

Halogen in the context of the invention generally represents fluorine, chlorine, bromine and iodine. Preference is given to fluorine, chlorine and bromine. Particular preference is given to fluorine and chlorine.

In the context of the invention, a 4- to 8-membered (preferably 5- to 7-membered) saturated heterocycle which is attached via a nitrogen atom and which optionally contains one further oxygen or sulphur atom represents, for example, pyrrolidin-1-yl, piperidin-1-yl, morpholin-4-yl, thiomorpholin-4-yl or 1*H*-hexahydroazepin-1-yl.

In the context of the invention, a 4- to 8-membered (preferably 5- to 7-membered) saturated heterocycle which contains a radical of the formula NR^7 and optionally additionally one nitrogen, oxygen or sulphur atom represents, for example, pyrrolidin-2-yl, 1-methylpyrrolidin-2-yl, pyrrolidin-3-yl, pyrazolidin-1-yl, piperidin-2-yl, 1-isopropyl-piperidin-3-yl, morpholin-2-yl, 4-cyclohexyl-piperazin-1-yl, thiomorpholin-3-yl, 1-ethyl-1H-hexahydroazepin-3-yl or 4-methyl-1H-hexahydro-1,4-diazepin-1-yl. This heterocycle can be attached to the imidazole ring via a ring carbon atom or a ring nitrogen atom.

Preference is given to compounds of the general formula (I) which have the absolute configuration given in the general formula (I')



(I'),

The compounds according to the invention can be present in four different relative configurations (A) to (D):



(A)



(B)



(C)



(D)

Preference is given to the configuration (D).

Preference is likewise given to compounds of the general formula (I) in which R^1 represents a radical of the formula $CO\text{-}NR^4R^5$ where R^4 and R^5 are each as defined above. Moreover, preference is given to those compounds of the general formula (I) in which R^2 contains a basic nitrogen atom.

Basic nitrogen atom is to be understood as meaning a nitrogen atom which, after protonation of the compound under aqueous standard conditions, has a pKa of more than 6.

Particular preference is given to compounds of the general formula (I) according to the invention

where

A, D, E and G each represent the CH group,

or one of the radicals A, D, E and G represents a nitrogen atom and the others each represent the CH group,

L^1 and L^2 are identical or different and independently of one another each represents one or more radicals selected from the group consisting of hydrogen, fluorine, chlorine, cyano, trifluoromethyl or trifluoromethoxy,

R^1 represents the $-CH_2-OH$ group, or
represents a radical of the formula $-CO-NR^4R^5$

in which

R^4 and R^5 are identical or different and each represents hydrogen or (C_1-C_3)-alkyl,

R^2 represents (C_3-C_7)-cycloalkyl,
represents (C_1-C_6)-alkyl which is optionally interrupted by an oxygen or sulphur atom or by a radical NR^6,
represents a 5- to 7-membered saturated heterocycle which is attached to the imidazole ring via a nitrogen atom and which optionally contains a further oxygen or sulphur atom, or
represents a 5- to 7-membered saturated heterocycle which contains a radical of the formula NR^7 and optionally additionally one nitrogen, oxygen or sulphur atom,

where (C_3-C_7)-cycloalkyl, (C_1-C_6)-alkyl which is optionally interrupted by one oxygen or sulphur atom, the 5- to 7-membered saturated heterocycle which is attached to the imidazole ring via a nitrogen atom and which optionally contains one further oxygen or sulphur atom and optionally (C_1-C_6)-alkyl which is interrupted by a radical NR^6 and optionally the 5- to 7-membered saturated heterocycle which contains a radical of the formula NR^7 and optionally additionally one nitrogen, oxygen or sulphur atom are substituted by a hydroxyl group and/or by a radical of the formula $-NR^8R^9$

in which

R^6 and R^7 are identical or different and each represents hydrogen, (C_1-C_4)-alkyl, hydroxy-(C_1-C_4)-alkyl or (C_3-C_6)-cycloalkyl,

R^8 and R^9 are identical or different and each represents hydrogen, (C_1-C_4)-alkyl or (C_3-C_6)-cycloalkyl,

or

R^8 and R^9 together with the nitrogen atom form a 5- to 7-membered saturated heterocycle which may optionally additionally contain one oxygen or sulphur atom or a radical of the formula NR^{10}

in which

R^{10} represents hydrogen, (C_1-C_4)-alkyl or (C_3-C_6)-cycloalkyl

and

R^3 represents a phenyl, pyridyl or thienyl ring which is optionally mono- or polysubstituted by radicals selected from the group consisting of fluorine, chlorine, cyano, trifluoromethyl or trifluoromethoxy,

and their salts.

Very particular preference is given to compounds of the general formula (I)

where

A, D and E each represent a CH group,

G represents a nitrogen atom or represents a CH group,

L^1 and L^2 each represent hydrogen,

R^1 represents a radical of the formula $-CO-NR^4R^5$,

in which

R^4 and R^5 each represent hydrogen,

R^2 represents (C_1-C_4)-alkyl which is optionally interrupted by one oxygen atom, or
represents a 4-R^7-piperazin-1-yl radical

where (C_1-C_4)-alkyl which is optionally interrupted by one oxygen atom is substituted by a hydroxyl group or by a radical of the formula $-NR^8R^9$

in which

R^7 represents hydrogen, (C_1-C_4)-alkyl or (C_3-C_6)-cycloalkyl,

R^8 and R^9 are identical or different and each represents hydrogen, (C_1-C_4)-alkyl or (C_3-C_6)-cycloalkyl,

or

R^8 and R^9 together with the nitrogen atom form a morpholine radical,

and

R^3 represents a phenyl radical,

and their salts.

Moreover, processes for preparing the compounds of the general formula (I) have been found which are characterized in that

[A] compounds of the general formula (II)



(II),

in which

L^2 is as defined above,

T represents $(C_1$-$C_4)$-alkyl, preferably methyl or tert-butyl,

and

V represents a suitable leaving group, such as, for example, halogen, mesylate or tosylate, preferably bromine,

is initially converted by reaction with compounds of the general formula (III)



(III),

in which

A, D, E, G and L^1 are each as defined in Claim 1

and

R^{11} has the meaning of R^2 given in Claim 1, where amino and hydroxyl functions are optionally blocked by suitable amino or hydroxyl protective groups,

in inert solvents, depending on the definition of R^{11} optionally in the presence of a base, into the compounds of the general formula (IV)



(IV),

in which

R^{11}, A, D, E, G, L^1, L^2 and T are each as defined above,

which are converted in a subsequent step using acids or bases into the corresponding carboxylic acids of the general formula (V)



(V),

in which

R^{11}, A, D, E, G, L^1 and L^2 are each as defined above,

which are subsequently, following activation, reacted by known methods with compounds of the general formula (VI)



(VI),

in which

R^1 and R^3 are each as defined above

in inert solvents,

and, if R^{11} carries one of the abovementioned protective groups, these are optionally removed by customary methods either in the hydrolysis to the acids (IV) -> (V) or after the reaction with the compounds of the general formula (VI),

or

[B] if R^2 represents a saturated heterocycle which is attached directly via a nitrogen atom to the imidazole ring,

the abovementioned compounds of the general formula (II) are initially converted with compounds of the general formula (IIIa)



(IIIa),

in which

A, D, E, G and L^1 are each as defined above

Y represents halogen or mesyl, preferably chlorine, bromine or mesyl,

in inert solvents into the corresponding compounds of the formula (VII)



(VII),

in which

Y, A, D, E, G, L^1, L^2 and T are each as defined above,

which are reacted in a subsequent step with compounds of the general formula (VIII)

$$HNR^{12}R^{13} \qquad \text{(VIII)}$$

in which

R^{12} and R^{13} together with the nitrogen atom form a heterocycle according to the definition of R^2

to give compounds of the general formula (IX)



(IX),

in which

A, D, E, G, L^1, L^2, R^{12}, R^{13} and T are each as defined above,

which are, in the subsequent steps, converted as described under [A] by hydrolysis into the corresponding carboxylic acids of the general formula (X)



(X),

in which

A, D, E, G, L^1, L^2, R^{12} and R^{13} are each as defined above,

and these compounds are subsequently, following activation, reacted with the compounds of the general formula (VI) according to known methods for preparing amides from carboxylic acids and amines and, if appropriate, converted into the corresponding salts by reaction with an acid.

The processes according to the invention can be illustrated in an exemplary manner by the formula schemes below:

[A]




N
N
N
N
O
COOH
H2N
CONH2
N
N
N
N
O
O
N
H
CONH2

[B]



Suitable amino protective groups in the context of the invention are the customary amino protective groups used in peptide chemistry.

These preferably include: benzyloxycarbonyl, 3,4-dimethoxybenzyloxycarbonyl, 3,5-dimethoxybenzyloxycarbonyl, 2,4-dimethoxybenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 2-nitrobenzyloxycarbonyl, 2-nitro-4,5-dimethoxybenzyloxycarbonyl, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl, isobutoxycarbonyl, tert-butoxycarbonyl, allyloxycarbonyl, vinyloxycarbonyl, 2-nitrobenzyloxycarbonyl, 3,4,5-trimethoxybenzyloxycarbonyl, cyclohexoxycarbonyl, 1,1-dimethylethoxycarbonyl, adamantylcarbonyl, phthaloyl, 2,2,2-trichloroethoxycarbonyl, 2,2,2-trichloro-tert-butoxycarbonyl, menthyloxycarbonyl, phenoxycarbonyl, 4-nitrophenoxycarbonyl, fluorenyl-9-methoxycarbonyl, formyl, acetyl, propionyl, pivaloyl, 2-chloroacetyl, 2-bromoacetyl, 2,2,2-trifluoroacetyl, 2,2,2-trichloroacetyl, benzoyl, 4-chlorobenzoyl, 4-bromobenzoyl, 4-nitrobenzoyl, phthalimido, isovaleroyl or benzyloxymethylene, 4-nitrobenzyl, 2,4-dinitrobenzyl or 4-nitrophenyl. A preferred protective group for primary amines is phthalimide. Preferred protective groups for secondary amines are benzyloxycarbonyl and tert-butoxycarbonyl.

The amino protective groups can be removed in a manner known per se, for example under the hydrogenolytic, acidic or basic conditions, preferably using acids, such as, for example, hydrochloric acid or trifluoroacetic acid, in inert solvents, such as ether, dioxane and methylene chloride.

A suitable hydroxy protective group in the context of the definition given above is generally a protective group from the series: trimethylsilyl, triethylsilyl, triisopropylsilyl, tert-butyl-dimethylsilyl, dimethylthexylsilyl, tert-butyl-diphenylsilyl, trimethylsilylethoxycarbonyl, benzyl, triphenylmethyl (trityl), monomethoxytrityl (MMTr), dimethyloxytrityl (DMTr), benzyloxycarbonyl, 2-nitrobenzyl, 4-nitrobenzyl, 2-nitrobenzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, tert-butyloxycarbonyl, 4-methoxybenzyl, 4-methoxybenzyloxycarbonyl, formyl, acetyl, trichloroacetyl, 2,2,2-trichloroethoxycarbonyl, 2,4-dimethoxybenzyl, 2,4-dimethoxybenzyloxycarbonyl, methoxymethyl, methylthiomethyl, methoxyethoxymethyl, [2-(trimethylsilyl)ethoxy]-methyl, 2-(methylthiomethoxy)ethoxycarbonyl, tetrahydropyranyl, benzoyl, N-succinimide, 4-methylbenzoyl, 4-nitrobenzoyl, 4-fluorobenzoyl, 4-chlorobenzoyl or 4-methoxybenzoyl. Preference is given to tert-butyldimethylsilyl.

The hydroxy protective group can be removed in a manner known per se, for example using acid or base, or by addition of tetrabutyl ammoniumfluoride, or is carried out during the hydrolysis of the carboxylic acid.

Suitable solvents for the processes are customary organic solvents which do not change under the reaction conditions. These include ethers, such as diethyl ether, dioxane, tetrahydrofuran, glycol dimethyl ether, or hydrocarbons, such as benzene, toluene, xylene, hexane, cyclohexane or mineral oil fractions, or halogenated hydrocarbons, such as dichloromethane, trichloromethane, tetrachloromethane, dichloroethylene, trichloroethylene or chlorobenzene, or ethyl acetate, pyridine, dimethyl sulphoxide, dimethylformamide, hexamethylphosphoric triamide, acetonitrile, acetone or nitromethane. It is also possible to use mixtures of the solvents mentioned. For the process [A] (II) + (III) → (IV), preference is given to diethyl ether, tetrahydrofuran and dimethylformamide. Particular preference is given to dimethylformamide.

Suitable for use as bases in the process according to the invention are, in general, inorganic or organic bases. These preferably include alkali hydroxides, such as, for example, sodium hydroxide or potassium hydroxide, alkaline earth metal hydroxides, such as, for example, barium hydroxide, alkali metal carbonates, such as sodium carbonate, potassium carbonate or caesium carbonate, alkaline earth metal carbonates, such as calcium carbonate, or alkali metal or alkaline earth metal alkoxides, such as sodium methoxide or potassium methoxide, sodium ethoxide or potassium ethoxide or potassium tert-butoxide, or organic amines (trialkyl(C_1-C_6)amines), such as triethylamine, or heterocycles, such as 1,4-diazabicyclo[2.2.2]octane (DABCO), 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU), pyridine, diaminopyridine, methylpiperidine or morpholine. It is also possible to use, as bases, alkali metals, such as sodium, or their hydrides, such as sodium hydride. Preference is given to sodium hydride, potassium carbonate, caesium carbonate, triethylamine, trimethylamine, pyridine, potassium tert-butoxide, DBU or DABCO. Very particularly preferred for the step [A](II) + (III) → (IV) is the use of sodium hydride.

In general, the bases are employed in an amount of from 0.05 mol to 10 mol, preferably from 1 mol to 2 mol, based on 1 mol of the compound of the formula (II).

The process (II) + (III) → (IV) according to the invention is generally carried out in a temperature range from -20°C to +60°C, preferably from 0°C to +60°C.

The process (II) + (III) → (IV) according to the invention is generally carried out under atmospheric pressure. However, it is also possible to carry out the process under elevated pressure or under reduced pressure (for example in a range from 0.5 to 5 bar.

The hydrolysis of the carboxylic esters is carried out by customary methods by treating the esters in inert solvents with customary bases, the salts which are formed initially being converted by treatment with acid into the free carboxylic acids, or, in the case of the t-butyl esters, with acid.

Suitable bases for the hydrolysis are the customary inorganic bases. These preferably include alkali metal hydroxides or alkaline earth metal hydroxides, such as, for example, sodium hydroxide, lithium hydroxide, potassium hydroxide or barium hydroxide, or alkali metal carbonates, such as sodium carbonate or potassium carbonate or sodium bicarbonate. Particular preference is given to using sodium hydroxide or lithium hydroxide.

Suitable acids are, in general, trifluoroacetic acid, sulphuric acid, hydrogen chloride, hydrogen bromide and acetic acid, or mixtures thereof, if appropriate with addition of water. Preference is given to hydrogen chloride or trifluoroacetic acid in the case of the tert-butyl esters and to hydrochloric acid in the case of the methyl esters.

Solvents which are suitable for the hydrolysis are water or organic solvents customarily used for hydrolysis. These preferably include alcohols, such as methanol, ethanol, propanol, isopropanol or butanol, or ethers, such as tetrahydrofuran or dioxane, dimethylformamide, dichloromethane or dimethyl sulphoxide. It is also possible to use mixtures of the solvents mentioned. Preference is given to water/tetrahydrofuran and, in the case of the reaction with trifluoroacetic acid, dichloromethane and, in the case of hydrogen chloride, tetrahydrofuran, diethyl ether or water.

The hydrolysis is generally carried out in a temperature range from 0°C to +100°C.

In general, the hydrolysis is carried out at atmospheric pressure. However, it is also possible to operate under reduced pressure or under elevated pressure (for example from 0.5 to 5 bar).

When carrying out the hydrolyses, the base or the acid is generally employed in an amount of from 1 to 100 mol, preferably from 1.5 to 40 mol, based on 1 mol of the ester.

The carboxylic acids (V) are usually activated by being converted into the corresponding acyl halides, preferably acyl chlorides, or pre-activation with a customary condensing agent, which can take place in situ or by isolating the activated carboxylic acid derivative. The acyl halides can be prepared by customary methods. The use of oxalyl chloride or thionyl chloride may be mentioned as an example.

Preferred auxiliaries used for the amide formations are condensing agents. Preference is given here to using the customary condensing agents, such as carbodiimides, for example N,N'-diethyl-, N,N'-dipropyl-, N,N'-diisopropyl-, N,N'-dicyclohexyl-carbodiimide, N-(3-dimethylaminoisopropyl)-N'-ethylcarbodiimide hydrochloride (EDC) or carbonyl compounds, such as carbonyldiimidazole, or 1,2-oxazolium compounds, such as 2-ethyl-5-phenyl-1,2-oxazolium-3-sulphate or 2-tert-butyl-5-methyl-isoxazolium perchlorate, or acylamino compounds, such as 2-ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline, or propanephosphonic acid anhydride, or isobutyl chloroformate, or bis-(2-oxo-3-oxazolidinyl)-phosphoryl chloride or benzotriazolyloxy-tri(dimethylamino)phosphonium hexafluorophosphate and, as bases, alkali metal carbonates, for example sodium carbonate or bicarbonate and potassium carbonate or bicarbonate, or organic bases, such as trialkylamines, for example triethylamine, N-ethylmorpholine, N-methylpiperidine or diisopropyl-ethylamine. Particular preference is given to the combination of EDC, N-methylmorpholine and 1-hydroxybenzotriazole. Preferred solvents for the amide formation are dichloromethane and DMF.

The compounds of the general formulae (II), (IIIa), (VI) and (VIII) are known or can be prepared by customary methods (cf. EP-A-0 725 061, EP-A-0 725 064).

Most of the compounds of the general formula (III) are novel, and they can be prepared, in the case that R^{11} does not represent a heterocycle which is attached directly via N, by reacting compounds of the general formula (XI)



(XI),

in which

A, D, E, G and L_1 are each as defined above

with compounds of the general formula (XII)

$$R^{11}\text{-}CO_2H \qquad \text{(XII)}$$

in which

R^{11} is as defined above

with removal of the water of reaction, if appropriate in the presence of an acid, preferably PPA, HCl and p-TsOH (cf. also *J. Org. Chem.* **1941**, *6*, 25 ff. and *Bull. Soc. Chim. Fr.* **1991**, *128*, 255-259)

and, in the case that R^{11} represents one of the radicals listed above under R^2 which may optionally also carry a protective group, by converting compounds of the general formula (XI) initially by reaction with compounds of the general formula (XIII)

$$HO\text{-}R^{14}\text{-}CO_2H \qquad \text{(XIII)}$$

in which

R^{14} represents $(C_1\text{-}C_8)$alkanediyl

into compounds of the general formula (XIV)



(XIV),

in which

A, B, D, G, R^{14} and L^1 are each as defined above

in inert solvents,

subsequently substituting the hydroxyl group by halogen, mesylate or tosylate, thus producing the compounds of the general formula (XV)



(XV)

in which

R^{14}, A, D, E, G and L^1 are each as defined above

and

Z represents halogen, mesylate or tosylate,

and reacting these with amines of the general formula (XVI)

$$R^8R^9NH \qquad (XVI)$$

in which

R^8 and R^9 are each as defined above

(cf. also *J. Am. Chem. Soc.* **1948**, *70*, f3406; *J. Heterocycl. Chem.* **1969**, 759-60).

Solvents which are suitable for the process are customary organic solvents which do not change under the reaction conditions. These preferably include ethers, such as diethyl ether, dioxane, tetrahydrofuran, glycol dimethyl ether, or hydrocarbons, such as benzene, toluene, xylene, hexane, cyclohexane or mineral oil fractions, or halogenated hydrocarbons, such as dichloromethane, trichloromethane, carbon tetrachloride, dichloroethylene, trichloroethylene or chlorobenzene, or ethyl acetate, triethylamine, pyridine, dimethyl sulphoxide, dimethylformamide, hexamethylphosphoric triamide, acetonitrile, acetone or nitromethane. It is also possible to use mixtures of the solvents mentioned. Preference is given to dichloromethane, tetrahydrofuran and dimethylformamide.

Bases suitable for use in the process according to the invention are, in general, inorganic or organic bases. These preferably include alkali metal hydroxides, such as, for example, sodium hydroxide or potassium hydroxide, alkaline earth metal hydroxides, such as, for example, barium hydroxide, alkali metal carbonates, such as sodium carbonate, potassium carbonate or caesium carbonate, alkaline earth metal carbonates, such as calcium carbonate, or alkali metal or alkaline earth metal alkoxides, such as sodium methoxide or potassium methoxide, sodium ethoxide or potassium ethoxide or potassium tert-butoxide, or organic amines (trialkyl(C_1-C_6)amines) such as triethylamine, or heterocycles such as 1,4-diazabicyclo[2.2.2]octane (DABCO), 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU), pyridine, diaminopyridine, methylpiperidine or morpholine. It is also possible to use, as bases, alkali metals, such as sodium, or their hydrides, such as sodium hydride. Preference is given to sodium hydride, potassium carbonate, triethylamine, trimethylamine, pyridine, potassium tert-butoxide, DBU or DABCO.

In general, the bases are employed in an amount of from 0.05 mol to 10 mol, preferably from 1 mol to 2 mol, based on 1 mol of the compound of the formula (XV).

The process according to the invention is generally carried out in a temperature range of from -50°C to +100°C, preferably from -30°C to +60°C.

The process according to the invention is generally carried out under atmospheric pressure. However, it is also possible to carry out the process under elevated pressure or under reduced pressure (for example in a range from 0.5 to 5 bar).

The compounds of the general formulae (XI), (XII), (XIII) and (XVI) are known per se or can be prepared by customary methods.

Some of the compounds of the general formulae (XIV) and (XV) are novel, and they can be prepared, for example, as described above.

The compounds of the general formulae (IV), (V), (VII), (IX) and (X) and their salts are novel and can be prepared as described above.

Surprisingly, the compounds of the general formula (I) according to the invention and their analogues have an unforeseeable useful pharmacological activity spectrum, combined with an improved solubility in water.

It has been found that the compounds according to the invention inhibit adenosine uptake.

They can be used orally or intravenously for the prophylaxis and treatment of cerebral ischaemia, stroke, reperfusion damage, brain trauma, oedema, spasms, epilepsy, respiratory arrest, cardiac arrest, Reye's syndrome, cerebral thrombosis, emboli, tumours, haemorrhages, encephalomyelitis, hydroencephalitis, spinal injuries, post-operative brain damage, injuries to the retina or the optical nerve after glaucoma, ischaemia, hypoxia, oedema or trauma and in the treatment of schizophrenia, sleep disturbances and pain.

Owing to their improved solubility in water, the compounds according to the invention are particularly suitable for intravenous administration.

Test systems

1. Determination of the solubility

To determine the solubility, a precipitation method was used:

10 mg of the test substance are completely dissolved in 50 µl of DMSO (stock solution). 20 µl of this solution are added to 2000 µl of physiological saline. This

solution, in turn, is shaken at 25°C in a Thermomixer Comfort (from Eppendorf) at 1400 rpm for 24 hours for equilibration.

The precipitated fractions of the test substance are centrifuged off using a Biofuge 15 from Heraeus at 14,000 rpm for 5 min. 1300 µl of the supernatant are once more centrifuged using a Microfuge from Beckmann at 45,000 rpm = 125,000 g.

10 µl of this centrifugation supernatant are then diluted with 1000 µl of DMSO, and this solution is measured by HPLC (Hewlett Packard 1090, method, gradient from 100% PBS buffer pH = 4 to 10% buffer/90% acetonitrile over a period of 15 min, column: RP18; PBS buffer pH = 4 is a physiological saline solution adjusted to pH = 4 using phosphate buffer).

Using a calibration curve, the measured peak area of the HPLC measurement is converted into substance concentration. For the calibration curve, 20 µl of the stock solution are diluted successively with DMSO such that 5 concentrations of 2.5 mg/l to 2000 mg/l result. These solutions are likewise measured by HPLC (see method above), and the peak areas are plotted as a function of the concentrations.

The solubility, determined by this method, of Examples 3 and 5 is 176 and 16 mg/l, respectively.

2. Binding of the compounds according to the invention to an adenosine transport protein from calf cortex

The ability of substances, to influence the adenosine uptake system is investigated firstly by determining the binding affinity of selected substances to an adenosine transport protein of the CNS and secondly by determining the inhibiting effect of the substances on functional adenosine uptake.

For the binding test, a membrane preparation of cerebral calf cortex is used, which expresses the relevant adenosine transporter. The binding affinity (K_i value) is determined by measuring the displacement of a specific radio-labelled ligand [nitrobenzylthioinosine (NBTI)] from the binding site in question by test substances. The binding site is the binding site on the transport protein which is relevant for the actual transport process. Thus, binding of test substances in this experiment results in

a quantifiable release of bound radioactive NBTI which makes determination of the K_i value possible. (*J. Neurochemistry* **1982**, *39*, 184-191).

Examples 3 and 5 inhibit NBTI-binding, in each case with K_i=2 nM.

3. Inhibition of adenosine uptake in calf cortex synaptosomes by compounds according to the invention

For the functional adenosine uptake test, a synaptosome preparation from cerebral calf cortex is used which expresses the adenosine transporter in question. Synaptosomes are cell-free, functionally active vesicles which are obtained from cortex tissue using sheer forces and which still have the properties of an intact synaptic knob. The inhibitory activity (IC_{50} value) is determined by measuring the inhibition of the uptake of the specific radio-labelled "substrate" adenosine into the synaptosomes (*J. Neurochemistry* **1990**, *55*, 541-550).
Examples 3 and 5 inhibit adenosine uptake into synaptosomes with IC_{50} = 8 nM and 14 nM, respectively.

The neuroprotective activity of the compounds according to the invention was determined in the animal model of transient occlusion of the middle cerebral artery (tMCA-O) and the subdural haematoma (SDH).

4. tMCA-O

This rodent model (rat) imitates the pathophysiology and cerebral pathology of stroke or circulatory arrest (embolization, thrombosis, vaso spasm, cardiac arrest, rapidly and dramatically reduced blood pressure, high blood loss, etc.) with subsequent recirculation in man (modified according to: *J. Cereb. Blood Flow Metab.* **1997**, *17*, 1066-1073).

Under general anaesthesia (inhalation anaesthesia with isoflurane), the hairs in the lower anterior neck region are shaved off, in the dorsal position, the head is fixed, the skin is disinfected and the neck area is opened in the middle along the trachea. The right lateral neck muscles are severed bluntly and, together with the skin, pulled to the side (retractors) so that the common carotid artery is clearly visible. The common carotid artery is exposed towards the head up to the point where it branches into the internal carotid artery and the external carotid artery. Using surgical suture material,

the common carotid artery (near the thorax) and the external carotid artery are tied off. Using a microclamp, the internal carotid artery is closed temporarily. The common carotid artery is opened, and a nylon monofilament with a rounded tip and a silicone cylinder of a length of 1 cm are passed through the common carotid artery and, after opening of the microclamp, further through the internal carotid artery, to close the exit of the middle cerebral artery. Using two temporary suture loops, the filament is fixed in the internal carotid artery. After one hour, the filament is pulled out, and the internal carotid artery and the common carotid artery are tied off above the opening. Blood is supplied via the contralateral muscular system.

Substance administration is begun directly with the start of reperfusion. The operation wound is surgically looked after. During the operation and the administration of the substance (infusion), the body temperature is kept constant using a heating plate.

After 2 days of post-operative survival, the volume of the cerebral infarct is determined with the aid of a computer-supported image analysis system using preproduced series of histological brain sections. The size of the infarct is evaluated differentially by cortex, striatum, hippocampus and other brain areas.

At a dose of 0.001 mg/(kg × h) (i.v. infusion), Examples 3 and 5 reduce the infarct volume by 81 and 91%, respectively, in comparison to control animals.

5. Subdural haematoma in rats (SDH)

This rodent model (rat) imitates pathophysiology and cerebral pathology of the blunt skull-brain trauma with subdural haemorrhage and development of a subdural haematoma in man. (*Neurosurgery* **1990**, *27*, 433-439).

Under anaesthesia, the animals are unilaterally injected subdurally with their own blood. Under the haematoma, an infarct forms. The substance is administered according to different schedules and via different administration routes (i.v., i.p.). The size of the infarct is determined as described in the model of the transient focal ischaemia in rats (tMCA-O).

At a dose of 0.001 mg/(kg × h) (i.v. infusion), Examples 3 and 4 reduce the infarct volume by 30 and 45%, respectively, in comparison to control animals.

The novel active compounds can be converted in a known manner into the customary formulations, such as tablets, coated tablets, pills, granules, aerosols, syrups, emulsions, suspensions and solutions, using inert, nontoxic, pharmaceutically suitable carriers or solvents. In this case the therapeutically active compound should in each case be present in a concentration of about 0.0001 to 90% by weight, preferably 0.0001 to 1.0% by weight, of the total mixture, i.e. in amounts which are sufficient in order to achieve the dosage range indicated.

The formulations are prepared, for example, by extending the active compounds with solvents and/or excipients, if appropriate using emulsifiers and/or dispersants, where, for example, if the diluent used is water, organic solvents can optionally be used as auxiliary solvents.

Administration is carried out in a customary manner, preferably orally, transdermally or parenterally, in particular perlingually or intravenously.

In general, it has proven advantageous in the case of intravenous administration to administer amounts of approximately 0.00001 to 10 mg/kg, preferably approximately 0.0001 to 1 mg/kg, of body weight to achieve effective results.

In spite of this, if appropriate, it may be necessary to depart from the amounts mentioned, namely depending on the body weight or the type of administration route, on the individual response to the medicament, the manner of its formulation and the time or interval at which administration takes place. Thus, in some cases it may be adequate to manage with less than the abovementioned minimum amount, while in other cases the upper limits mentioned must be exceeded. In the case of the administration of relatively large amounts, it may be advisable to divide these into several individual doses over the course of the day.

Abbreviations

DMF:	N,N-dimethylformamide
DMSO:	dimethyl sulphoxide
PPA:	polyphosphoric acid
TFA:	trifluoroacetic acid
THF:	tetrahydrofuran

Starting materials

Example 1A

(1*R*, 2*R*)-23-(4-Methyl-phenyl)-cyclohexane-1-carboxylic acid



Racemic (1*R**,2*R**)-2-(4-methyl-phenyl)-cyclohexane-1-carboxylic acid was prepared analogously to the process described in US-A-5,395,840, column 16. The resulting racemic material was separated into the enantiomers using the following procedure:

The racemic acid (415 g; 1.9 mol) and triethylamine (96.2 g; 0.95 mol; 131.8 ml) were suspended in a mixture of THF (2.7 l) and water (5.3 l). At 60°C, S-(-))-phenylethylamine (115.2 g; 0.95 mol) was added dropwise, resulting in a precipitate being formed. The mixture was stirred at 60°C for 2 h and then cooled using an ice-bath. The precipitate was filtered off with suction, giving predominantly the phenylethylamine salt of the (1S,2S)-enantiomer. The filtrate was acidified using conc. HCl and extracted twice using dichloromethane. The combined extracts were dried over sodium sulphate and concentrated. Yield: 202.4 g (28%) of a mixture of enantiomers enriched with the (1*R*,2*R*)-isomer.

This mixture was treated with R-(+)-phenylethylamine as described above to precipitate the desired enantiomer as a salt. The colourless crystals were filtered off with suction and recrystallized from acetonitrile/methanol (6:1). X-ray analysis of these crystals confirmed the (1*R*, 2*R*)-configuration. Yield 136.9 g (46%). Work-up (see above) gave 89 g of (1*R*, 2*R*)-2-(4-methylphenyl)-cyclohexane-1-carboxylic acid.

Example 2A

Tert-butyl (1*R*, 2*R*)-2-(4-bromomethyl-phenyl)-cyclohexane-1-carboxylate:



The intermediate was prepared analogously to the procedure for the racemate (US-A-5,395,840, column 17). For purification, the resulting mixture was stirred with diethyl ether.

Example 3A

2-(2-Phthalimidylethyl)-benzimidazole



2-Aminoethylbenzimidazole dihydrochloride (*Bull. Soc. Chim. Fr. 1991, 128*, 255-259; 2.34 g, 10 mmol), phthalic anhydride (1.63 g, 11 mmol) and triethylamine (2.79 ml, 20 mmol) in chloroform (25 ml) were heated at reflux overnight , and the mixture was then cooled to room temperature, diluted with ethyl acetate and filtered off. The filtrate was washed with saturated sodium carbonate solution, buffer (pH = 7) and saturated sodium chloride solution and dried over sodium sulphate. Chromatography (dichloromethane:methanol 10:1, R_f = 0.4) gave 2.08 g of 2-(2-phthalimidylethyl)-benzimidazole (71.4% of theory) as a colourless foam. MS (DCI, NH_3) = 292 ($M+H^+$). ^{1}H-NMR (DMSO-d_6): 3.15 (2 H, t); 4.0 (2 H, t); 7.05-7.2 (2 H, m); 7.4-7.5 (2 H, m); 7.8-7.9 (4 H, m); 12.4 (1 H, br s).

The remainder of the synthesis is carried out following the general procedures A, B and C as mentioned below, and in the last step, the phthalimide group is cleaved off as described below.

Example 4A

2-(2-Hydroxyethoxymethyl)-pyrido[2,3-*d*]imidazole



1,4-Dioxan-2-one (6.13 g, 60 mmol) and 2,3-diaminopyridine (5.46 g, 50 mmol) in mesitylene (100 ml) were heated at reflux in a Dean-Stark separator for 10 h. After cooling, mesitylene was decanted off and the residue was purified by silica gel chromatography (dichloromethane:methanol 9:1) (yield: 8.47 g, 87% of theory).

MS(DCI)=194 (M+H, 100%); ^{1}H-NMR (DMSO-d_6): 3.78 (2H, m); 3.89 (2H, m); 4.91 (2H, s); 5.3 (1H, s); 7.18 (1H, dd); 7.95 (1H, d); 8.43 (1H, dd); 12.7 (1H, br s).

Example 5A

2-[2-(*tert*-Butyldimethylsilyloxy)ethoxymethyl]-pyrido[2,3-*d*]imidazole



8.4 g (43.48 mmol) of 2-(2-hydroxyethoxymethyl)-(pyrido-[2,3-d]-1*H*-imidazole) and 4.84 g (47.82 mmol) of triethylamine were dissolved in 120 ml of DMF and admixed with 7.21 g (47.8 mmol) of TBDMS chloride, the mixture warming to about 40°C. Stirring at room temperature was continued for 2 h, and the mixture was then poured into water, giving the product in crystalline form. The product was filtered off with suction, washed with a little water and dried under high vacuum. ^{1}H-NMR (DMSO-d_6): 0.02 (6H, s); 0.83 (9H, s); 3.52 (2H, t); 3.75 (2H, t); 4.73 (2H, s); (1H, dd); 7.90 (1H, dd); 8.43 (1H, dd); 12.9 (1H, br s).

Example 6A

2-*tert*-Butyldimethylsilyloxymethyl-benzimidazole:



At room temperature, triethylamine (2.27 ml, 16.3 mmol) and TBDMS chloride (1.65 g, 10.95 mmol) were added to a solution of 2-hydroxymethylbenzimidazole (1.4 g, 9.95 mmol) in DMF (30 ml). After 3.5 h, the reaction was terminated by addition of water, the mixture was extracted with diethyl ether and the organic phase was dried over sodium sulphate. Chromatography (silica gel, cyclohexane:ethyl acetate 2:1, R_f=0.35) gave 2.52 g of 2-*tert*-butyldimethylsilyloxymethylbenzimidazole (97% of theory) as a brownish powder. MS (DCI, NH_3) = 263 ($M+H^+$). ^{1}H-NMR (DMSO-d_6): 0.00 (6H, s); 0.80 (9H, s); 4.75 (2H, s); 7.0-7.1 (2H, m); 7.4-7.5 (2H, m); 12.15 (1H, br s).

Example 7A

2-(2-Hydroxyethoxymethyl)-benzimidazole:



Using a Dean-Stark separator, 1,4-dioxan-2-one (2.04 g, 20 mmol) and 1.2-diaminobenzene (2.16 g, 20 mmol) were heated under reflux in mesitylene (150 ml) for 10 h. The crystals formed on cooling were then filtered off with suction (2.94 g, 77% of theory). R_f (dichloromethane:methanol 10:1) = 0.45, MS (EI) = 192 (M^+, 20%), 148 (20%), 147 (40%), 132 (100%), ^{1}H-NMR (DMSO-d_6): 3.6 (4H, s); 4.65 (1H, s); 4.7 (2H, s); 7.1-7.2 (2H, m); 7.45 (1H, d); 7.55 (1H, d); 12.4 (1H, br s).

General alkylation procedure [A]:

In a typical batch, sodium hydride (6.3 mmol) was, at 0°C, added to a solution of the imidazole of the general formula (III) (6 mmol) in dry DMF (30 ml). After 30 min at room temperature and 30 min at 40°C, the compound of the general formula (II) (6.3 mmol) was added at 0°C, and the reaction mixture was stirred at room temperature overnight. The reaction was then terminated by addition of water, the mixture was extracted with diethyl ether and the organic phase was then dried over sodium sulphate. Chromatography (silica gel, cyclohexane:ethyl acetate) gave the product in a yield of 60-70%.

General procedure for ester hydrolysis [B]:

In a typical batch, trifluoroacetic acid (5 ml) was added at room temperature to a solution of the ester of the general formula (IV) (T = *tert*-Bu; 1.5 mmol) in dichloromethane (5 ml). After 2 h, the mixture was cooled to 0°C, adjusted to pH = 2 using aqueous sodium hydroxide solution (about 30 ml, 2M) and extracted with

dichloromethane. Drying of the organic phase over sodium sulphate gave, after concentration, the compound of the general formula (V).

General procedure for amide formation [C]:

A suspension of acid (V) (4 mmol), *(S)*-phenylglycinamide hydrochloride (4.2 mmol), 1-hydroxybenzotriazole (4.4 mmol), EDC hydrochloride (4.8 mmol) and triethylamine (12 mmol) in dichloromethane (40 ml) was stirred at room temperature for 24-48 h. Water was added, and the mixture was then extracted with dichloromethane (in some cases with methanol) and the organic phase was dried over sodium sulphate (or magnesium sulphate) and chromatographed (silica gel, dichloromethane:methanol). This gave the desired product in a yield of 60-80%.

Analogously to procedure C, it is possible to employ phenylglycinol instead of phenylglycinamide.

Preparation examples

Example 1

***(S)*-N-{(1*R**, 2*R**)-{4-[2-(2-Aminoethyl-benzimidazol-1-yl)methyl]phenyl}-cyclohex-2-yl-carbonyl}-phenylglycinamide**



A suspension of *(2S)*-N-[*(2R*)*-(4-{2-(2-phthaloylaminoethyl)-benzimidazol-1-yl-methyl}-phenyl)-cyclohexyl-*(1R*)*-carbonyl]-phenylglycinamide (prepared according to the general procedures [A-C] from the compound of Example 3A and the racemate of Example 2A according to US-A-5,395,840, Example IV; 500 mg, 0.78 mmol, mixture of diastereomers) in ethanol (25 ml) was admixed with hydrazine hydrate (0.38 ml, 7.82 mmol). The mixture was stirred at room temperature overnight and then adjusted to pH = 2 using hydrochloric acid (1M) and concentrated. Partition between 10% aqueous sodium bicarbonate solution and dichloromethane, drying of the organic phase over sodium sulphate and chromatography (silica gel, dichloromethane:methanol:conc. aqueous ammonia 100:13:1.3, Rf(10:1:0.2) = 0.1) gave the title compound (292 mg, 72%, mixture of diastereomers) as a yellowish powder. MS (DCI, NH_3) = 510 ($M+H^+$). ^{1}H-NMR (DMSO-d_6): 1.2-1.5 (4H, m); 1.6-1.9 (4H, m); 2.0 (2H, br s); 2.6-3.0 (6H, m); 5.1-5.2 (A:1H, d; B:1H, d); 5.4-5.5 (A:2H, s; B:2H, s); 6.85-7.0 (4H, m); 7.1-7.3 (7H, m); 7.4-7.5 (1H, m); 7.55-7.65 (4H, m); 8.05-8.15 (A:1H, d; B:1H, d).

Example 2

***(S)*-N-{(1*R*, 2*R*)-{4-{[2-(2-Aminoethyl)-benzimidazol-1-yl)methyl}phenyl}-cyclohex-1-yl-carbonyl}phenylglycinamide dihydrochloride**



Chromatographic separation of the starting material from Example 1 (silica gel, methylene chloride:methanol) gave diastereomerically pure *(S)*-(N)-{(1*R*, 2*R*)-2-{4-{2-[2-(phthaloyl-amino)-ethyl]-benzimidazol-1-yl}methyl}-phenyl}-cyclohex-1-yl-carbonyl}-phenylglycinamide which was deprotected analogously to Example 1 and then dissolved in as small amount of dichloromethane as possible, treated with approximately 2 equivalents of 1M HCl in diethyl ether and concentrated.

Found: C 64.21 H 6.58

Calc.: C 63.91 H 6.49

Example 3

***(S)*-N-{{(1*R*, 2*R*)-{4-{2-[2-(Morpholin-4-yl-methyl)-1*H*-pyrido[2,3-d]imidazol-1-yl]methyl}-phenyl}-cyclohex-1-yl}carbonyl}-phenylglycinamide**



a) 2-Hydroxymethyl-1*H*-pyrido[2,3-*d*]imidazole



using a Dean-Stark separator, 2,3-diaminopyridine (54.6 g; 0.5 mol) and glycolic acid (38 g; 0.5 mol) in 700 ml of mesitylene were boiled under reflux until the calculated amount of water had separated off. The mixture was then cooled to room temperature, and the resulting precipitate was filtered off with suction and, with addition of activated carbon, boiled in 800 ml of water for 15 min. The hot suspension was filtered and once more cooled to room temperature, and the colourless crystals that precipitated out were filtered off with suction and dried. Yield: 56.4 g (75%).

b) 2-Chloromethyl-1*H*-pyrido[2,3-*d*]imidazole hydrochloride:



HCl

The compound from Example 3a (14.9 g; 100 mmol) was suspended in 25 ml of ethanol, and a stream of dry HCl was introduced until the mixture was saturated. The resulting hydrochloride was filtered off with suction and dried under reduced pressure. Yield 18.1 g (100%). This was suspended in 100 ml of chloroform and mixed with 35 ml of thionyl chloride. The mixture was then heated under reflux for 24 h and filtered whilst still hot, and the precipitate was washed with chloroform and dried under reduced pressure. Yield 18.9 g (92%).

c) 2-(Morpholin-4-yl-methyl)-1*H*-pyrido[2,3-*d*]imidazole:



The compound from Example 3b (13.7 g; 67 mmol) and morpholine (28.6 g; 328 mmol) were boiled under reflux for 3 h. The mixture was concentrated and the residue was taken up in sodium bicarbonate solution. This suspension was, with addition of activated carbon, boiled for 15 min and subsequently filtered whilst still hot. The mixture was concentrated and the resulting product was then purified by column chromatography (silica gel (70-230 mesh ASTM); mobile phase: 100:30:1 ethyl acetate/ethanol/triethylamine). The product can be recrystallized from ethyl acetate/hexane.

d) *tert*-Butyl (1*R*, 2*R*)-{4-{[2-(morpholin-4-yl-methyl)-1*H*-pyrido[2,3-*d*]imidazol1yl]methyl}-phenyl}-cyclohexane-1-carboxylate



Under argon, a 60% strength suspension of sodium hydride in oil (2 g; 51.6 mmol) was suspended in 150 ml of DMF, and the compound from Example 3c (9.5 g; 43.5 mmol) was added. The mixture was heated at 50°C for 30 min, and a precipitate formed. The mixture was then cooled to room temperature and the compound from Example 2A (17.3 g; 44 mmol) was added, and the mixture was then stirred at room temperature for 20 h. The resulting clear solution was concentrated under high

vacuum and the residue was taken up in dichloromethane/water. The organic phase was separated off, dried over sodium sulphate and concentrated. The residue was then purified by column chromatography (silica gel (70-230 mesh ASTM); mobile phase: 100:4 dichloromethane/methanol). Yield 10 g (47%) of a brown viscose oil.

e) (1*R*,2*R*)-2-{4-{[2-(Morpholin-4-yl-methyl)-1*H*-pyrido[2,3-*d*]imidazol-1-yl]methyl}phenyl}cyclohexane-1-carboxylic acid



The compound from Example 3d (10g; 20.4 mmol), 120 ml of dichloromethane and 100 ml of trifluoroacetic acid were stirred at room temperature for 1 h. With cooling, the mixture was then neutralized with conc. aqueous sodium hydroxide solution and the org. phase was separated off, dried and concentrated. The residue was purified by column chromatography (mobile phase: dichloromethane/methanol 100:6). Yield 7.3 g (80%) of a colourless amorphous solid.

f) *(S)*-N-{{(1*R*,2*R*)-2-{4-{[2-(Morpholin-4-yl-methyl)-1*H*-pyrido[2,3-*d*]imidazol-1-yl]methyl}-phenyl}-cyclohex-1-yl}carbonyl}-phenylglycinamide



According to the general process [C], the compound from Example 3e (1.4 g; 3.22 mmol) was reacted with addition of a spatular tip of DMAP (4-dimethylaminopyridine). For work-up, the product was extracted with dichloromethane and purified by column chromatography (dichloromethane/methanol 100:6). Yield 1.7 g (93%) of a pale yellowish powder.

^{1}H-NMR (300 MHz; $CDCl_3$) δ[ppm]: 1.25-1.5 (3H; br m), 1.62 (1H; dq), 1.8 (3H; m), 1.94 (1H; dd), 2.31 (1H; dt), 2.42 (4H, br m), 2.67 (1H; dt), 3.61 (6H; m), 5.21 (1H; d), 5.49 (1H, br s), 5.63 (2H; d+d), 5.72 (1H; br s), 6.41 (1H; d), 6.82 (2H; d), 6.92 (2H; d), 6.98 (2H; d), 7.13 (2H, t), 7.18 (1H; t), 7.23 (1H; dd), 8.03 (1H; d), 8.42 (1H; d)

MS (DCI/NH_3)[m/z]: 567 (100, M+H)

Example 4

***(S)*-N-{{(1*R*,2*R*)-{4-{2[2-(Morpholin-4-yl-methyl)-1*H*-pyrido[2,3-*d*]imidazol-1-yl]methyl}-phenyl}-cyclohex-1-yl}carbonyl}-phenylglycinamide hydrochloride**

The compound from Example 3 was completely dissolved in as small an amount of dichloromethane as possible and treated with approximately 2 equivalents of 1M-HCl in diethyl ether. The resulting precipitate was filtered off with suction [m.p. 158 °C (decomp.)].

Example 5

***(S)*-N-{{(1*R*,2*R*)-2-{4-{[2-(4-Methyl-piperazin-1-yl)-benzimidazol-1-yl]methyl}-phenyl}-cyclohex-1-yl}carbonyl}-phenylglycinamide**

a) *tert*-butyl (1*R*,2*R*)-2-{4-[(2-Chloro-benzimidazol-1-yl)methyl]-phenyl}-cyclohexane-1-carboxylate



According to the general procedure [A], the title compound was prepared from 2-chlorobenzimidazole and the compound from Example 2A [R_f (cyclohexane:ethyl acetate = 1:1) = 0.85].

b) (1*R*,2*R*)-2-{4-{[2-(4-Methyl-piperazin-1-yl)-benzimidazol-1-yl]methyl}-phenyl}-cyclohexane-1-carboxylic acid



A solution of the compound from Example 5a (34.0 g, 56.0 mmol) in N-methylpiperazine (77.7 ml, 700 mmol) was heated at 100°C overnight and then concentrated and chromatographed (silica gel, dichloromethane:methanol = 20:1 to 10:1, R_f (10:1) = 0.32). This gave 32.0 g of *tert*-butyl (1*R*,2*R*)-2-{4-{[2-(4-methyl-piperazin-1-yl)-benzimidazol-1-yl]methyl}-phenyl}-cyclohexan-1-carboxylate which were reacted at room temperature with hydrochloric acid (180 ml, 6M) overnight. The reaction mixture was washed at pH = 7 with dichloromethane and the organic phase was dried over magnesium sulphate and chromatographed (silica gel, dichloromethane:methanol 5:1, R_f = 0.13), giving 19 g (78% of theory over 2 steps)

of the title compound. MS (ESI) = 433 ($M+H^+$). ^{1}H-NMR (DMSO-d_6):1.35-1.5 (4H, m); 1.65-1.8 (3H, m); 1.9-2.0 (1H, m); 2.2 (3H, s); 2.4-2.5 (5H, m); 2.6-2.7 (1H, m); 3.15 (4H, ψ t); 3.4 (1H, very br s); 5.2 (2H, s); 7.0-7.2 (7H, m); 7.4 (1H, d).

c) *(S)*-N-{{(1*R*,2*R*)-2-{4-{[2-(4-Methyl-piperazin-1-yl)-benzimidazol-1-yl]methyl}-phenyl}-cyclohex-1-yl}carbonyl}-phenylglycinamide



A suspension of the compound from Example 5b (19 g, 43.9 mmol), *(S)*-phenylglycinamide hydrochloride (8.61 g, 46.1 mmol), 1-hydroxybenzotriazole (7.68 g, 48.3 mmol), EDC hydrochloride (9.68 g, 50.5 mmol) and triethylamine (24.5 ml, 175.7 mmol) in dichloromethane (1000 ml) was stirred at room temperature over the weekend. Water was added, the mixture was then extracted with dichloromethane/methanol and the extract was dried over magnesium sulphate and concentrated. The slightly yellowish solid was stirred in dichloromethane/methanol (10:1, 220 ml) and the clean title compound was filtered off with suction and dried under reduced pressure at 40°C (14.5 g, 59%). R_f (dichloromethane:methanol 10:1) = 0.30. MS (4DCI, NH_3) = 565 ($M+H^+$). ^{1}H-NMR (DMSO-d_6): 1.2-1.5 (4H, m); 1.6-1.85 (4H, m); 2.2 (3H, s); 2.45 (4H, ψ t); 2.65 (1H, br t); 2.8 (1H, td); 3.15 (4H, ψ t); 5.15 (1H, d); 5.2 (2H, s); 6.9 (2H, d); 6.95-7.2 (11H, m); 7.45 (1H, d); 7.6 (1H, br s); 8.0 (1H, d).

Example 6

***(S)*-N-{{(1*R*,2*R*)-2-{4-{[2-(4-Methyl-piperazin-1-yl)-benzimidazol-1-yl]methyl}-phenyl}-cyclohex-1-yl}carbonyl}-phenylglycinamide hydrochloride**



The compound from Example 5 (100 mg, 0.177 mmol) was dissolved in dichloromethane/methanol (2.5:1; 5 ml) and admixed with 1M HCl/diethyl ether (0.177 mmol), and the mixture was stirred for 5 minutes and then concentrated under reduced pressure in the cold. The title compound was obtained as a colourless powder (106 mg). M.p. 200°C (decomp.).

The Examples 7 to 10 listed in Table 1 below were prepared analogously to Example 5, using the corresponding substituted piperazines.

Table 1:

Ex. No.	Structure	R_f *
7		0.3 (10:1:0)
8		0.3 (10:1:0.1)

Ex. No.	Structure	R_f *
9		0.4 (10:1:0.1)
10		0.3 (10:1:0.1)

* CH_2Cl_2:methanol:conc. ammonia

The examples 11 and 12 listed in Table 2 below are prepared according to the general procedures A, B and C, starting with the compound from Example 6A.

Table 2:

Ex. No.	Structure	R_f *
11		0.4 (10:1)
12		0.35 (10:1)

* CH_2Cl_2:methanol

Example 13

***(S)*-N-{{(1*R*,2*R*)-2-{4-{[2-(2-Hydroxyethoxy)methyl]-benzimidazol-1-yl}methyl}-phenyl}-cyclohex-1-yl}carbonyl}-phenylglycinamide**



Starting from the compound of Example 7A which is silylated with TBDMS chloride analogously to Example 6A and then reacted according to the general procedures A, B and C, the title compound is obtained.

R_f (dichloromethane:methanol 20:1) = 0.20.

MS (ESI) = 541 ($M+H^+$). ^{1}H-NMR (DMSO-d_6): 1.2-1.5 (4H, m); 1.6-1.9 (4H, m); 2.6-2.7 (1H, m); 2.75-2.85 (1H, m); 3.5 (4H, s); 4.65 (1H, br s); 4.6 (2H, s); 5.15 (1H, d); 5.55 (2H, s); 6.9 (2H, d); 6.95-7.2 (10H, m); 7.45 (1H, m); 7.6 (1H, s); 7.65 (1H, m); 8.05 (1H, d).

Examples 14 to 16 listed in Table 3 below are prepared analogously to Example 13 from the appropriate starting materials.

Table 3:

Ex. No.	Structure	R_f (CH_2Cl_2:MeOH: conc. ammonia)	MS
14		0.44 (10:1:0)	
15		0.46 (10:1:0)	
16			EI: 541 (M÷)

Patent claims

1. Compounds of the general formula (I)



(I),

in which

A, D, E and G are identical or different and represent CH groups or nitrogen atoms,

L1 and L2 are identical or different and independently of one another each represents one or more radicals selected from the group consisting of hydrogen, halogen, hydroxyl, carboxyl, cyano, nitro, trifluoromethyl, trifluoromethoxy, (C1-C6)-alkyl, (C1-C6)-alkoxy or (C1-C6)-alkoxy-carbonyl,

R^1 represents the CH_2-OH group, or
represents a radical of the formula $CO\text{-}NR^4R^5$

in which

R^4 and R^5 are identical or different and each represents hydrogen or $(C_1\text{-}C_6)$-alkyl,

R^2 represents $(C_3\text{-}C_8)$-cycloalkyl,
represents $(C_1\text{-}C_8)$-alkyl which is optionally interrupted by an oxygen or sulphur atom or by a radial NR^6,
represents a 4- to 8-membered saturated heterocycle which is attached to the imidazole ring via a nitrogen atom and which optionally contains a further oxygen or sulphur atom, or

represents a 4- to 8-membered saturated heterocycle which contains a radical of the formula NR^7 and optionally additionally one nitrogen, oxygen or sulphur atom,

where (C_3-C_8)-cycloalkyl, (C_1-C_8)-alkyl which is optionally interrupted by one oxygen or sulphur atom, the 4- to 8-membered saturated heterocycle which is attached to the imidazole ring via a nitrogen atom and which optionally contains one further oxygen or sulphur atom and optionally (C_1-C_8)-alkyl which is interrupted by a radical of the formula NR^6 and optionally the 4- to 8-membered saturated heterocycle which contains a radical of the formula NR^7 and optionally additionally one nitrogen, oxygen or sulphur atom are substituted by one to three hydroxyl groups and/or by a radical of the formula $-NR^8R^9$

in which

R^6 and R^7 are identical or different and each represents hydrogen, (C_1-C_6)-alkyl, hydroxy-(C_1-C_6)-alkyl or (C_3-C_7)-cycloalkyl,

R^8 and R^9 are identical or different and each represents hydrogen, (C_1-C_6)-alkyl or (C_3-C_7)-cycloalkyl,

or

R^8 and R^9 together with the nitrogen atom form a 4- to 8-membered saturated heterocycle which may optionally additionally contain one oxygen or sulphur atom or a radical of the formula NR^{10}

in which

R^{10} represents hydrogen, (C_1-C_6)-alkyl or (C_3-C_7)-cycloalkyl

and

R^3 represents a phenyl, naphthyl, pyrimidinyl, pyridyl, furyl or thienyl ring, where the rings are optionally mono- or polysubstituted by radicals selected from the group consisting of halogen, hydroxyl, carboxyl, cyano, nitro, trifluoromethyl, trifluoromethoxy, (C_1-C_6)-alkyl, (C_1-C_6)-alkoxy or (C_1-C_6)-alkoxycarbonyl,

and their salts.

2. Compounds according to Claim 1

where

A, D, E and G each represent the CH group,

or one of the radicals A, D, E and G represents a nitrogen atom and the others each represent the CH group,

L^1 and L^2 are identical or different and independently of one another each represents one or more radicals selected from the group consisting of hydrogen, fluorine, chlorine, cyano, trifluoromethyl or trifluoromethoxy,

R^1 represents the $-CH_2-OH$ group, or
represents a radical of the formula $-CO-NR^4R^5$

in which

R^4 and R^5 are identical or different and each represents hydrogen or (C_1-C_3)-alkyl,

R^2 represents (C_3-C_7)-cycloalkyl,
represents (C_1-C_6)-alkyl which is optionally interrupted by an oxygen or sulphur atom or by a radical NR^6,
represents a 5- to 7-membered saturated heterocycle which is attached to the imidazole ring via a nitrogen atom and which optionally contains a further oxygen or sulphur atom, or

represents a 5- to 7-membered saturated heterocycle which contains a radical of the formula NR^7 and optionally additionally one nitrogen, oxygen or sulphur atom,

where (C_3-C_7)-cycloalkyl, (C_1-C_6)-alkyl which is optionally interrupted by one oxygen or sulphur atom, the 5- to 7-membered saturated heterocycle which is attached to the imidazole ring via a nitrogen atom and which optionally contains one further oxygen or sulphur atom and optionally (C_1-C_6)-alkyl which is interrupted by a radical of the formula NR^6 and optionally the 5- to 7-membered saturated heterocycle which contains a radical of the formula NR^7 and optionally additionally one nitrogen, oxygen or sulphur atom are substituted by one to three hydroxyl groups and/or by a radical of the formula $-NR^8R^9$

in which

R^6 and R^7 are identical or different and each represents hydrogen, (C_1-C_4)-alkyl, hydroxy-(C_1-C_4)-alkyl or (C_3-C_6)-cycloalkyl,

R^8 and R^9 are identical or different and each represents hydrogen, (C_1-C_4)-alkyl or (C_3-C_6)-cycloalkyl,

or

R^8 and R^9 together with the nitrogen atom form a 5- to 7-membered saturated heterocycle which may optionally additionally contain one oxygen or sulphur atom or a radical of the formula NR^{10}

in which

R^{10} represents hydrogen, (C_1-C_4)-alkyl or (C_3-C_6)-cycloalkyl

and

R^3 represents a phenyl, pyridyl or thienyl ring which is optionally mono- or polysubstituted by radicals selected from the group consisting of fluorine, chlorine, cyano, trifluoromethyl or trifluoromethoxy,

and their salts.

3. Compounds according to Claim 1

where

A, D and E each represent a CH group,

G represents a nitrogen atom or represents a CH group,

L^1 and L^2 each represent hydrogen,

R^1 represents a radical of the formula $-CO-NR^4R^5$,

in which

R^4 and R^5 each represent hydrogen,

R^2 represents (C_1-C_4)-alkyl which is optionally interrupted by one oxygen atom, or
represents a 4-R^7-piperazin-1-yl radical

where (C_1-C_4)-alkyl which is optionally interrupted by one oxygen atom is substituted by a hydroxyl group or by a radical of the formula $-NR^8R^9$

in which

R^7 represents hydrogen, (C_1-C_4)-alkyl or (C_3-C_6)-cycloalkyl,

R^8 and R^9 are identical or different and each represents hydrogen, (C_1-C_4)-alkyl or (C_3-C_6)-cycloalkyl,

or

R^8 and R^9 together with the nitrogen atom form a morpholine radical,

and

R^3 represents a phenyl radical,

and their salts.

4. (*S*)-N-{{(1*R*, 2*R*)-2-{4-{[2-(4-Methyl-piperazin-1-yl)-benzimidazol-1-yl]methyl}-phenyl}-cyclohex-1-yl}carbonyl}-phenylglycinamide



and its salts.

5. Process for preparing compounds of the general formula (I) according to Claims 1 to 4, characterized in that

[A] compounds of the general formula (II)



(II),

in which

L^2 is as defined in Claim 1,

T represents (C_1-C_4)-alkyl, preferably methyl or tert-butyl,

and

V represents a suitable leaving group, such as, for example, halogen, mesylate or tosylate, preferably bromine,

is initially converted by reaction with compounds of the general formula (III)



(III),

in which

A, D, E, G and L^1 are each as defined in Claim 1

and

R^{11} has the meaning of R^2 given in Claim 1, where amino and hydroxyl functions are optionally blocked by suitable amino or hydroxyl protective groups,

in inert solvents, depending on the definition of R^{11} optionally in the presence of a base, into the compounds of the general formula (IV)



(IV),

in which

R^{11}, A, D, E, G, L^1, L^2 and t are each as defined above,

which are converted in a subsequent step using acids or bases into the corresponding carboxylic acids of the general formula (V)



(V),

in which

R^{11}, A, D, E, G, L^1 and L^2 are each as defined above,

which are subsequently reacted by known methods with compounds of the general formula (VI)



(VI),

in which

R^1 and R^3 are each as defined in Claim 1

in inert solvents,

and, if R^{11} carries one of the abovementioned protective groups, these are optionally removed by customary methods either in the hydrolysis to the acids (IV) -> (V) or after the reaction with the compounds of the general formula (VI),

or

[B] if R^2 represents a saturated heterocycle which is attached directly via a nitrogen atom to the imidazole ring,

the abovementioned compounds of the general formula (II) are initially converted with compounds of the general formula (IIIa)



(IIIa),

in which

A, D, E, G and L^1 are each as defined in Claim 1

and

Y represents halogen or mesyl, preferably chlorine, bromine or mesyl,

in inert solvents into the corresponding compounds of the formula (VII)



(VII),

in which

Y, A, D, E, G, L^1, L^2 and T are each as defined above,

which are reacted in a subsequent step with compounds of the general formula (VIII)

$$HNR^{12}R^{13} \qquad \text{(VIII)}$$

in which

R^{12} and R^{13} together with the nitrogen atom form a heterocycle according to the definition of R^2

to give compounds of the general formula (IX)



(IX),

in which

A, D, E, G, L^1, L^2, R^{12}, R^{13} and T are each as defined above,

which are, in the subsequent steps, converted as described under [A] by hydrolysis into the corresponding carboxylic acids of the general formula (X)



(X),

in which

A, D, E, G, L^1, L^2, R^{12} and R^{13} are each as defined above,

and these compounds are subsequently reacted with the compounds of the general formula (VI) according to known methods for preparing amides from carboxylic acids and amines and, if appropriate, converted into the corresponding salts by reaction with an acid.

6. Compounds of the general formula (IV)



(IV),

in which

A, D, E, G, L^1, L^2, R^{11} and T are each as defined in Claims 1 and 5

and their salts.

7. Compounds of the general formula (V)



(V),

in which

A, D, E, G, L^1, L^2 and R^{11} are each as defined in Claims 1 and 5

and their salts.

8. Compounds of the general formula (VII)



(VII),

in which

A, D, E, G, L^1, L^2, Y and T are each as defined in Claims 1 and 5

and their salts.

9. Compounds of the general formula (IX)



(IX)

in which

A, D, E, G, L^1, L^2, R^{12}, R^{13} and T are each as defined in Claims 1 and 5

and their salts.

10. Compounds of the general formula (X)



(X),

in which

A, D, E, G, L^1, L^2, R^{11} and R^{12} are each as defined in Claims 1 and 5

and their salts.

11. Medicaments, comprising a compound of the general formula (I) according to any of Claims 1 to 4 in admixture with at least one pharmaceutically acceptable, essentially non-toxic carrier or excipient.

12. Compounds according to any of Claims 1 to 4 for use as medicament in the treatment of humans and animals.

13. Use of compounds according to any of Claims 1 to 4 for preparing medicaments for the treatment and/or prophylaxis of ischaemic brain disorders.

14. Use of compounds according to any of Claims 1 to 4 for preparing medicaments for the treatment and/or prophylaxis of stroke, reperfusion damage or brain trauma.

COMBINED DECLARATION AND POWER OF ATTORNEY	ATTORNEY DOCKET NO Le A 33 469

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name. I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought
on the invention entitled

SUBSTITUTED PHENYLCYCLOHEXANE CARBOXYLIC ACID AMIDES THAT HAVE AN ADENOSINE UPTAKE INHIBITING EFFECT

the specification of which is attached hereto,

or was filed on **May 16, 2000**

as a PCT Application Serial No. **PCT/EP00/04417**

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims.

I acknowledge the duty to disclose information which is material to the patentability of this application in accordance with Title 37, Code of Federal Regulations, §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s), the priority(ies) of which is/are to be claimed:

199 24 818.4	**Germany**	**May 29, 1999**
(Number)	(Country)	(Month/Day/Year Filed)

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose the material information as defined in Title 37, Code of Federal Regulations, §1.56 which occured between the filing date of the prior application and the national or PCT international filing date of this application:

(Application Serial No.)	(Filing Date)	(Status) (patented, pending, abandoned)
(Application Serial No.)	(Filing Date)	(Status) (patented, pending, abandoned)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

Jeffrey M. Greenman, Reg.No. 26552
Barbara A. Shimei, Reg. No. 29862
William F. Gray, Reg. No. 31018
Alice A. Brewer, Reg. No. 32888
Jerrie L. Chiu, Reg. No. 41670

Susan M. Pellegrino, Reg. No. 48,972

all of Bayer Corporation, 400 Morgan Lane, West Haven, Connecticut 06516

Send Correspondence To: **Mr. Jeffrey M. Greenman** **Bayer Corporation** **400 Morgan Lane** **West Haven, Connecticut 06516**	**Direct Telephone Calls To:** **(203)812-3964(Jerrie L. Chiu)**

FULL NAME OF SOLE OR FIRST INVENTOR Wolf-Dietrich Freund	INVENTOR'S SIGNATURE Wolf-Dietrich Freund	DATE 7. Nov. 01
RESIDENCE D 42799 Leichlingen, Germany DEX		CITIZENSHIP German
POST OFFICE ADDRESS c/o Bayer Aktiengesellschaft, D 51368 Leverkusen, Germany		
FULL NAME OF SECOND INVENTOR Stephan Lensky	INVENTOR'S SIGNATURE	DATE 6.Nov.01
RESIDENCE D 51515 Kürten, Germany DEX		CITIZENSHIP US
POST OFFICE ADDRESS c/o Bayer Aktiengesellschaft, D 51368 Leverkusen, Germany		
FULL NAME OF THIRD INVENTOR Stephan Nicholas Müller	INVENTOR'S SIGNATURE Stephan-Nicholas Müller	DATE 07.11.2001
RESIDENCE D 42105 Wuppertal, Germany DEX		CITIZENSHIP German
POST OFFICE ADDRESS c/o Bayer Aktiengesellschaft, D 51368 Leverkusen, Germany		
FULL NAME OF FOURTH INVENTOR Holger Paulsen	INVENTOR'S SIGNATURE Holger Paulsen	DATE 8.11.2001
RESIDENCE D 42115 Wuppertal, Germany DEX		CITIZENSHIP German
POST OFFICE ADDRESS c/o Bayer Aktiengesellschaft, D 51368 Leverkusen, Germany		
FULL NAME OF FIFTH INVENTOR Jörg Keldenich	INVENTOR'S SIGNATURE Jörg Keldenich	DATE 7.11.01
RESIDENCE D 42113 Wuppertal, Germany DEX		CITIZENSHIP German
POST OFFICE ADDRESS c/o Bayer Aktiengesellschaft, D 51368 Leverkusen, Germany		
FULL NAME OF SIXTH INVENTOR Ervin Horváth	INVENTOR'S SIGNATURE Ervin Horváth	DATE 12.11.01
RESIDENCE D 51373 Leverkusen, Germany DEX		CITIZENSHIP German
POST OFFICE ADDRESS c/o Bayer Aktiengesellschaft, D 51368 Leverkusen, Germany		
FULL NAME OF SEVENTH INVENTOR Joachim Schuhmacher	INVENTOR'S SIGNATURE Joachim Schuhmacher	DATE 15.11.01
RESIDENCE D 42113 Wuppertal, Germany DEX		CITIZENSHIP German
POST OFFICE ADDRESS c/o Bayer Aktiengesellschaft, D 51368 Leverkusen, Germany		